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B a c k g r o u n d
G o n o r rh e a  is th e  s e c o n d  m o s t c o m m o n ly  re p o r te d  n o t i f ia b le  d ise a se  in th e  U n ite d  S ta te s , w ith  
3 0 9 ,3 4 1  cases re p o r te d  in 2 0 1 0  [1 ] . A lth o u g h  th e  n a t io n a l g o n o r rh e a  ra te  d e c re a s e d  2 1 .7 %  
d u r in g  2 0 0 0 -2 0 1 0 , f r o m  1 2 8 .7  to  1 0 0 .8  c a s e s /1 0 0 ,0 0 0  p o p u la t io n ,  fu tu r e  p ro g re s s  in g o n o r rh e a  
c o n tr o l  a n d  p re v e n t io n  is th r e a te n e d  b y  re s is ta n c e  to  an  in c re a s in g  n u m b e r  o f  a n t im ic ro b ia l  
a g e n ts  a n d  l im ite d  re m a in in g  t r e a tm e n t  o p t io n s .
O v e r  th e  y e a rs , N e i s s e r i a  g o n o r r h o e a e  has re a d ily  a c q u ire d  re s is ta n c e  to  a b ro a d  s p e c tru m  o f  
a n t im ic ro b ia l  a g e n ts  t r a d i t io n a l ly  used  f o r  th e  t r e a tm e n t  o f  g o n o c o c c a l in fe c t io n s . In th e  
U n ite d  S ta te s , th e  a n t im ic ro b ia l  s u s c e p t ib i l i ty  p a t te rn s  o f  N . g o n o r r h o e a e  h a ve  b e e n  c lo s e ly  
m o n ito r e d  s in c e  1 9 8 6  th r o u g h  th e  G o n o c o c c a l Is o la te  S u rv e illa n c e  P ro je c t (G ISP), a n d  th e  
in fo rm a t io n  has b e e n  used  to  u p d a te  t r e a tm e n t  re c o m m e n d a t io n s .  In 2 0 1 0 , 2 7 .2 %  o f  a ll GISP 
is o la te s  w e re  re s is ta n t to  p e n ic il l in ,  te t ra c y c l in e ,  c ip ro f lo x a c in ,  o r  s o m e  c o m b in a t io n  o f  th o s e  
a n t im ic ro b ia ls  a n d  6 .9 %  o f  is o la te s  w e re  re s is ta n t to  a ll th r e e  a n t im ic ro b ia ls  [1 ] . P e n ic ill in , 
te t ra c y c l in e ,  a n d  f lu o r o q u in o lo n e  a n t im ic ro b ia ls  a re  n o  lo n g e r  re c o m m e n d e d  as a p p ro p r ia te  
t r e a tm e n t  f o r  g o n o r rh e a  in  th e  U n ite d  S ta te s . C u r re n t ly ,  th e  C e n te rs  fo r  D isease  C o n tro l a n d  
P re v e n t io n  (CDC) re c o m m e n d s  d u a l th e r a p y  w ith  c e f t r ia x o n e  (an  in je c ta b le  c e p h a lo s p o r in )  2 5 0  
m g  in tra m u s c u la r ly  as a s in g le  d o s e  p lu s  e i th e r  a z ith ro m y c in  1 g ra m  o ra l ly  as a s in g le  d o s e  o r  
d o x y c y c lin e  1 0 0  m g  o ra l ly  tw ic e  a d a y  f o r  7 d a ys  as th e  m o s t e f fe c t iv e  t r e a tm e n t  f o r  
u n c o m p lic a te d  g o n o r rh e a  [2 , 3 ] . F o r p a t ie n ts  a lle rg ic  to  c e p h a lo s p o r in s , a z ith ro m y c in  2 g ra m s  
o ra l ly  as a s in g le  d o s e  is th e  o n ly  a l te rn a t iv e  t r e a tm e n t  o p t io n  a v a ila b le ; h o w e v e r ,  th e  use o f  
m o n o th e ra p y  w ith  a z ith ro m y c in  s h o u ld  be  e x tre m e ly  ju d ic io u s  d u e  to  c o n c e rn s  a b o u t  p o s s ib le  
ra p id  e m e rg e n c e  o f  a z ith ro m y c in  re s is ta n c e . O th e r  p o te n t ia l  t r e a tm e n t  o p t io n s  f o r  g o n o r rh e a  
a re  e i th e r  n o t  a v a ila b le  in th e  U n ite d  S ta te s , d o  n o t  m e e t c lin ic a l e f fe c t iv e n e s s  c r i te r ia  f o r  
re c o m m e n d e d  t r e a tm e n t ,  o r  h a ve  n o t  b e e n  a d e q u a te ly  s tu d ie d . T h e re fo re ,  th e  e m e rg e n c e  a n d  
s p re a d  o f  c e p h a lo s p o r in - re s is ta n t  N . g o n o r r h o e a e  (C e p h -R  N G ) w o u ld  s e v e re ly  l im i t  t r e a tm e n t  
o p t io n s  f o r  g o n o r rh e a  in th e  U n ite d  S ta te s .
T h e  e m e rg e n c e  o f  C eph -R  NG in th e  U n ite d  S ta te s  c o u ld  o c c u r  e i th e r  th r o u g h  th e  im p o r ta t io n  
o f  C eph -R  NG f r o m  o th e r  c o u n tr ie s ,  th r o u g h  g e n e t ic  t r a n s fo rm a t io n s  b y  o b ta in in g  g e n e tic  
m a te r ia l f r o m  o th e r  o rg a n is m s , o r  th r o u g h  d o m e s t ic  d ru g  s e le c t io n  p re s s u re s  in  th e  U n ite d  
S ta te s . W h ile  m u ta t io n s  th r o u g h  d ru g  s e le c t io n  p re s s u re s  g e n e ra l ly  ta k e  t im e ,  th e  m o re  ra p id  
in t r o d u c t io n  o f  a n t im ic ro b ia l- r e s is ta n t  N . g o n o r r h o e a e  s tra in s  to  th e  U n ite d  S ta te s  th r o u g h  th e  
im p o r ta t io n  o f  re s is ta n t s tra in s , fo l lo w e d  b y  s u b s e q u e n t t ra n s m is s io n  o f  re s is ta n t s tra in s  
th r o u g h  lo c a l se xu a l n e tw o rk s  has a lw a y s  b e e n  a c o n c e rn .
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In th e  la s t d e c a d e , N . g o n o r r h o e a e  s tra in s  w ith  d e c re a s e d  s u s c e p t ib i l i ty  to  c e p h a lo s p o r in s  h a ve  
b e e n  re p o r te d  w ith  in c re a s in g  f r e q u e n c y  f r o m  c o u n tr ie s  in A s ia  a n d  th e  P a c ific  re g io n  [4 -1 0 ] , as 
w e ll as f r o m  E u ro p e , C a n a da , a n d  th e  U n ite d  S ta te s  [2 , 1 1 , 1 2 ] . C e fix im e  t r e a tm e n t  fa i lu re s  
w e re  f i r s t  re p o r te d  f r o m  Ja p a n  in 2 0 0 3  [6 ] a n d  ha ve  s u b s e q u e n t ly  b e e n  re p o r te d  f r o m  N o rw a y , 
th e  U n ite d  K in g d o m , A u s tr ia ,  a n d  F ra n ce  [1 3 - 1 7 ] . M o re  re c e n t ly ,  a n d  o f  g re a t c o n c e rn , a 
g o n o c o c c a l is o la te  w ith  h ig h - le v e l c e f t r ia x o n e  re s is ta n c e  w a s  id e n t i f ie d  in  a J a p a n e se  w o m a n  
w ith  p h a ry n g e a l in fe c t io n  a n d  a p p a re n t  c e f t r ia x o n e  t r e a tm e n t  fa i lu re  in  2 0 0 9  [1 0 ] . G o n o c o c c a l 
is o la te s  w ith  h ig h - le v e l c e f t r ia x o n e  re s is ta n c e  h a ve  s u b s e q u e n t ly  b e e n  id e n t i f ie d  in  m e n  w ith  
u ro g e n ita l in fe c t io n s  in  F ra n ce  a n d  in S pa in  [1 7 , 1 8 ] .
W h ile  c o n f irm e d  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re s  h a ve  n o t  y e t  b e e n  id e n t i f ie d  in  th e  U n ite d  
S ta te s , GISP has d e te c te d  re c e n t in c re a s e s  in  m in im u m  in h ib i to r y  c o n c e n tra t io n s  (M IC s ) fo r  
c e p h a lo s p o r in s  a m o n g  g o n o c o c c a l is o la te s  in  th e  U n ite d  S ta te s . F ro m  2 0 0 6  to  th e  f i r s t  s ix  
m o n th s  o f  2 0 1 1 , th e  p ro p o r t io n  o f  GISP is o la te s  w ith  an  e le v a te d  c e f ix im e  M IC  (M IC  > 0 .2 5  
H g /m l)  in c re a s e d  f r o m  0 .1 %  to  1 .7% , a n d  th e  p ro p o r t io n  w ith  an  e le v a te d  c e f t r ia x o n e  M IC  (M IC  
> 0 .1 2 5  n g /m l)  in c re a s e d  f r o m  0 .0 5 %  to  0 .5 %  [1 9 ] . T h e s e  in c re a s e s  w e re  m o s t n o ta b le  in  th e  
w e s te rn  U n ite d  S ta te s  a n d  a m o n g  M S M . In th e  W e s t, th e  p ro p o r t io n  o f  is o la te s  w ith  an 
e le v a te d  c e f ix im e  M IC  in c re a s e d  f r o m  0 .2 %  to  3 .6%  a n d  th e  p ro p o r t io n  w ith  an  e le v a te d  
c e f t r ia x o n e  M IC  in c re a s e d  f r o m  0 .0 4 %  to  1 .9% . A m o n g  M S M , th e  p ro p o r t io n  w ith  an  e le v a te d  
c e f ix im e  M IC  in c re a s e d  f r o m  0 .2 %  to  4 .7 % , a n d  th e  p ro p o r t io n  w ith  an  e le v a te d  c e f t r ia x o n e  
M IC  in c re a s e d  f r o m  0%  to  1 .0% . T h e re  is c o n c e rn  th a t  th is  p a t te rn  is re m in is c e n t  o f  th e  p a t te rn  
t h a t  w a s  se e n  w ith  th e  e m e rg e n c e  o f  f lu o r o q u in o lo n e - r e s is ta n t  N . g o n o r r h o e a e  (Q R N G ): 
d e te c t io n  f i r s t  in  H a w a ii a n d  th e n  th e  w e s te rn  U n ite d  S ta te s , b e fo re  s p re a d in g  w id e ly  in  th e  
c o n t in e n ta l  U n ite d  S ta te s . W h ile  th e  f i r s t  Q R N G  cases w e re  d e te c te d  a m o n g  h e te ro s e x u a ls , 
Q R N G  b e c a m e  w id e s p re a d  in th e  c o n t in e n ta l  U n ite d  S ta te s  a m o n g  m e n  w h o  h a ve  sex  w ith  m e n  
(M S M ) w ith  g o n o r rh e a  b e fo re  b e c o m in g  w id e s p re a d  a m o n g  h e te ro s e x u a ls  [2 0 - 2 2 ] .
I t  is l ik e ly  C eph -R  NG in fe c t io n s  w il l  e m e rg e  in  th e  U n ite d  S ta te s . A  s ig n if ic a n t  c h a lle n g e  to  
d e v e lo p in g  an e f fe c t iv e  re s p o n s e  s tr a te g y  is th e  la ck  o f  a s u c c e s s fu l m o d e l f o r  p re v e n t io n  a n d  
c o n tr o l  o f  a n t im ic ro b ia l- r e s is ta n t  N . g o n o r r h o e a e .  In  p re v io u s  e f fo r ts  to  a d d re s s  th e  e m e rg e n c e  
o f  p e n ic il l in a s e -p ro d u c in g  N . g o n o r r h o e a e  (PPN G ) [2 3 ] a n d  Q R N G  [2 0 -2 2 ] , CDC a n d  th e  U n ite d  
S ta te s  p u b lic  h e a lth  c o m m u n ity  h a ve  b e e n  u n a b le  to  p re v e n t  o r  c o n tr o l  th e  in t r o d u c t io n  a n d  
s p re a d  o f  a n t im ic ro b ia l- r e s is ta n t  N . g o n o r r h o e a e ,  e v e n  w h e n  m o re  e f fe c t iv e  a l te rn a t iv e  
a n t im ic ro b ia l  o p t io n s  w e re  a v a ila b le  a n d  g re a te r  re s o u rc e s  w e re  a v a ila b le  f o r  p a t ie n t  a n d  
p a r tn e r  fo l lo w -u p .
L im it in g  th e  im p a c t  o f  a n t im ic ro b ia l- r e s is ta n t  N . g o n o r r h o e a e  w i l l  re q u ire  a c o n c e r te d  a n d  
s u s ta in e d  e f f o r t  in v o lv in g  m u lt id is c ip l in a ry  g ro u p s . A lth o u g h  n e w  d ru g  c lasses o r  s y n e rg is t ic
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c o m b in a t io n s  o f  d i f fe r e n t  a n t im ic ro b ia ls  m a y  be id e n t i f ie d  f o r  th e  t r e a tm e n t  o f  C eph -R  NG a n d  
m u lt id ru g - r e s is ta n t  N . g o n o r r h o e a e ,  i t  is c r it ic a l t o  p re p a re  f o r  th e  e m e rg e n c e  o f  C e p h -R  NG in 
th e  c u r r e n t  r e a l ity  o f  l im ite d  t r e a tm e n t  o p t io n s  a n d  l im ite d  p u b lic  h e a lth  re s o u rc e s . T h is  p u b lic  
h e a lth  re s p o n s e  p la n  id e n t i f ie s  s tra te g ie s  f o r  e n h a n c e d  s u rv e illa n c e  to  d e te c t  th e  e m e rg e n c e  o f  
C e ph -R  NG in th e  U n ite d  S ta te s  a n d  o u t l in e s  p ro g ra m m a t ic  s te p s  th a t  can  be ta k e n  to  m it ig a te  
th e  im p a c t u n t i l  c o s t-e f fe c t iv e  t r e a tm e n t  a lte rn a t iv e s  ca n  be id e n t i f ie d .  T h e  e ffe c t iv e n e s s  o f  
th is  p la n  s h o u ld  be  c lo s e ly  m o n ito r e d ,  a n d  th e  p la n  s h o u ld  be  p e r io d ic a l ly  re v ie w e d  a n d  
re v is e d , ba se d  o n  u p d a te d  s u rv e illa n c e , e p id e m io lo g ic a l a n d  c lin ic a l d a ta .
O b j e c t i v e s
General Objective
T h is  d o c u m e n t  is in te n d e d  to  be  a re s o u rc e  f o r  s ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts  in o r d e r  to  
m in im iz e  th e  im p a c t  o f  C eph -R  NG o n  th e  p re v e n t io n  a n d  c o n tr o l  o f  g o n o r rh e a  a n d  its  s e q u e la e  
a t th e  c o m m u n ity  le v e l in  th e  U n ite d  S ta te s .
Specific Objectives
(1 ) T o  e s ta b lis h  e n h a n c e d  s u rv e illa n c e  fo r  p a t ie n ts  w ith  s u s p e c t o r  p ro b a b le  C eph -R  NG 
in fe c t io n s  (see  case  d e f in i t io n s ,  pa g e s  8 - 9 )
(2 ) T o  o u t l in e  th e  re c o m m e n d e d  p u b lic  h e a lth  a c t io n s  to  be  im p le m e n te d  a t th e  n a t io n a l,  
s ta te , a n d  lo c a l le v e ls  fo l lo w in g  d e te c t io n  o f  s u s p e c t o r  p ro b a b le  C e ph -R  NG cases
S u r v e i l l a n c e  f o r  C e p h - R  N G
CDC c u r r e n t ly  c o n d u c ts  s u rv e illa n c e  f o r  a n t im ic ro b ia l  re s is ta n c e  a m o n g  N . g o n o r r h o e a e  is o la te s  
th r o u g h  GISP [2 4 ] . S ince  its  in c e p t io n  in 1 9 8 6 , GISP has s u c c e s s fu lly  d e te c te d  t r e n d s  in 
re s is ta n c e , p ro v id e d  p re v a le n c e  d a ta , a n d  d ir e c t ly  in fo rm e d  CDC t r e a tm e n t  re c o m m e n d a t io n s  
f o r  g o n o r rh e a . H o w e v e r , b e ca u se  GISP is a s e n t in e l s u rv e illa n c e  s y s te m  th a t  o n ly  c o n d u c ts  
s u rv e illa n c e  o n  is o la te s  f r o m  s y m p to m a t ic  m e n  a t te n d in g  s e le c te d  s e x u a lly  t r a n s m it te d  d ise a se  
(STD) c lin ic s , a n d  b e ca u se  i t  ta k e s  t im e  to  p ro c e s s  is o la te s  a n d  m e a s u re  M IC s  th r o u g h  G ISP's 
n e tw o r k  o f  re fe re n c e  la b o ra to r ie s , th e r e  is a n e e d  f o r  a d d it io n a l,  m o re  s e n s it iv e  a n d  t im e ly  
s u rv e illa n c e  a p p ro a c h e s  in  o r d e r  to  d e te c t  th e  e m e rg e n c e  o f  c e p h a lo s p o r in  re s is ta n c e .
T h e  e x p a n d e d  s u rv e illa n c e  a p p ro a c h  w il l  u t i l iz e  c lin ic a l d e te c t io n  a n d  re p o r t in g  o f  s u s p e c t a n d  
p ro b a b le  C eph -R  NG cases in  a d d it io n  to  c o n t in u e d  s u rv e illa n c e  th r o u g h  GISP. Local
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s u rv e illa n c e  c o u ld  be  e x p a n d e d  fu r t h e r  b y  e s ta b lis h in g  a n e tw o rk  o f  c lin ic s  w h e re  g o n o r rh e a  is 
c o m m o n ly  d ia g n o s e d , a n d  im p le m e n t in g  c u ltu re -b a s e d  te s t in g  a n d  m o n ito r in g  o f  a n t im ic ro b ia l 
s u s c e p t ib i l i ty  o f  is o la te s . S ta te  a n d  lo c a l h e a lth  d e p a r tm e n ts  c o u ld  a lso  e n h a n c e  s u rv e illa n c e  by  
m o n ito r in g  a n d  in v e s t ig a t in g  p a t ie n ts  w ith  m u lt ip le  re p o r ts  o f  N . g o n o r rh o e a e  in fe c t io n  w ith in  
th e  p re c e d in g  30  d a ys  o r  6 0  d a ys  to  d e te r m in e  w h e th e r  such  re p o r ts  a re  p o s s ib le  t r e a tm e n t  
fa i lu re s  (see  p o s s ib le  o p t io n s  f o r  e n h a n c in g  s u rv e illa n c e , pag e  5 ). T o g e th e r  w ith  d a ta  f r o m  
GISP, f in d in g s  f r o m  e x p a n d e d  s u rv e illa n c e  w il l  in fo rm  fu tu r e  CDC re c o m m e n d a t io n s  fo r  
g o n o r rh e a  t r e a tm e n t ,  s c re e n in g , a n d  te s t  o f  c u re .
Clinicians
C lin ic ia n s  a re  re q u e s te d  to  (1 ) m a in ta in  v ig ila n c e  f o r  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re s , (2) 
o b ta in  s p e c im e n s  fo r  c u l tu re  a n d  a n t im ic ro b ia l  s u s c e p t ib i l i ty  te s t in g  (AST) f r o m  p a t ie n ts  
e x p e r ie n c in g  p o s s ib le  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re  as d e s c r ib e d  b e lo w , a n d  (3 ) re p o r t  cases 
t h a t  m e e t th e  c r i te r ia  f o r  s u s p e c t o r  p ro b a b le  C eph -R  NG in fe c t io n  (see case d e f in i t io n s ,  pages 
8 - 9 )  to  th e  s ta te  o r  lo c a l h e a lth  d e p a r tm e n t .
(1 ) D e te c t in g  p o s s ib le  c e p h a lo s p o r in  t r e a tm e n t  fa i lu r e .  C e p h a lo s p o r in  t r e a tm e n t  fa i lu re  is 
th e  p e rs is te n c e  o f  N . g o n o r r h o e a e  in fe c t io n  d e s p ite  a p p ro p r ia te  c e p h a lo s p o r in  
t r e a tm e n t ,  a n d  c o u ld  in d ic a te  in fe c t io n  w ith  C eph -R  NG . P a tie n ts  d ia g n o s e d  w ith  
g o n o r rh e a  s h o u ld  be  e d u c a te d  a b o u t  C e p h -R  NG a n d  in s tru c te d  to  re tu rn  to  c a re  if  
s y m p to m s  d o  n o t  re s o lv e  w it h in  3 - 5  d a ys  o r  i f  te s t  o f  c u re  is re c o m m e n d e d . P a tie n ts  
a lso  s h o u ld  be  in fo rm e d  o f  th e  n e e d  f o r  t h e i r  p a r tn e rs  to  be  t r e a te d  a n d  a d v is e d  to  
a v o id  se x  f o r  o n e  w e e k  fo l lo w in g  t r e a tm e n t .
T re a tm e n t  fa i lu re  d u e  to  C e ph -R  NG in fe c t io n  s h o u ld  be  c o n s id e re d  in :
•  P a tie n ts  w h o s e  s y m p to m s  d o  n o t  re s o lv e  w ith in  3 -5  d a ys  a f te r  a p p ro p r ia te  
t r e a tm e n t  a n d  w h o  re p o r t  n o  se xu a l c o n ta c t  d u r in g  th e  p o s t - t r e a tm e n t  fo l lo w -  
u p  p e r io d
•  P a tie n ts  w ith  a p o s it iv e  te s t  o f  c u re  (p o s it iv e  c u ltu re  > 7 2  h o u rs  o r  p o s it iv e  
n u c le ic  a c id  a m p l if ic a t io n  te s t  [N A A T ] >7  d a ys  a f te r  a p p ro p r ia te  t r e a tm e n t )  w h e n  
n o  s e xu a l c o n ta c t  is r e p o r te d  d u r in g  th e  p o s t - t r e a tm e n t  fo l lo w - u p  p e r io d
•  P a tie n ts  w ith  a p o s it iv e  N . g o n o r r h o e a e  c u l tu re  w ith in  3 0 - 6 0  d a ys  (b u t  > 7 2  
h o u rs )  a f t e r  t r e a tm e n t  f o r  g o n o r rh e a  w h o  a re  fo u n d  to  h a ve  e le v a te d  
c e p h a lo s p o r in  M IC s  o n  AST (see  la b o ra to r y  c r i te r ia  f o r  s u s p e c t o r  p ro b a b le  C e p h - 
R NG cases, pages 7 - 8 ) ,  re g a rd le s s  o f  w h e th e r  s e xu a l c o n ta c t  is re p o r te d  d u r in g  
th e  p o s t - t r e a tm e n t  fo l lo w - u p  p e r io d
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(2 ) O b ta in in g  s p e c im e n s  f o r  c u l tu r e  a n d  A ST . C lin ic ia n s  s h o u ld  o b ta in  c u ltu re  s p e c im e n s  
f o r  AST f r o m  p a t ie n ts  w ith  p o s s ib le  t r e a tm e n t  fa i lu re .  In a d d it io n ,  c lin ic ia n s  s h o u ld  a lso  
c o n s id e r  o b ta in in g  c u ltu re  s p e c im e n s  f r o m  p a t ie n ts  w h o  h a ve  b e e n  d ia g n o s e d  w ith  
a n o th e r  N . g o n o r r h o e a e  in fe c t io n  in  th e  p a s t 3 0 - 6 0  da ys , e v e n  w h e n  re - in fe c t io n  c a n n o t 
be  e x c lu d e d . C lin ic ia n s  s e rv in g  p o p u la t io n s  a t  in c re a s e d  r is k  f o r  g o n o r rh e a  ( i.e ., s e x u a lly  
a c t iv e  p a t ie n ts  w ith  o n e  o r  m o re  o f  th e  fo l lo w in g  r is k  fa c to rs :  age  < 2 5  y e a rs , h is to ry  o f  
p re v io u s  g o n o r rh e a  in fe c t io n  o r  o th e r  s e x u a lly  t r a n s m it te d  in fe c t io n ,  n e w  o r  m u lt ip le  
se x  p a r tn e rs , in c o n s is te n t  c o n d o m  use , sex  w o rk ,  o r  d ru g  use [2 5 ] ) s h o u ld  e s ta b lis h  
g o n o c o c c a l c u l tu re  p ro c e d u re s  in  t h e i r  c lin ic a l s e tt in g s  th a t  can  be  im p le m e n te d  w h e n  a 
case w ith  p o s s ib le  t r e a tm e n t  fa i lu re  is id e n t i f ie d .
(3 ) R e p o r t in g .  C ases th a t  m e e t th e  c r i te r ia  f o r  s u s p e c t o r  p ro b a b le  C e p h -R  NG in fe c t io n  
(see  case  d e f in i t io n s ,  pages 8 - 9 )  s h o u ld  be  re p o r te d  to  th e  s ta te  o r  lo ca l h e a lth  
d e p a r tm e n t .  C lin ic ia n s  s h o u ld  a lso  c o n ta c t  th e  s ta te  o r  lo ca l h e a lth  d e p a r tm e n t  i f  th e r e  
is c o n c e rn  a b o u t C e ph -R  NG in fe c t io n  in a p a t ie n t  w h o  d o e s  n o t  m e e t th e  case d e f in i t io n  
o r  i f  th e y  re q u ire  a s s is ta n c e  o b ta in in g  access  to  c u l tu re  a n d  AST.
Laboratorians
L a b o ra to r ia n s  a re  re q u e s te d  t o  re p o r t  N . g o n o r r h o e a e  is o la te s  th a t  m e e t la b o ra to ry -b a s e d  
c r i te r ia  f o r  s u s p e c t o r  p ro b a b le  C e ph -R  NG (see  case d e f in i t io n s ,  pa g e s  8 - 9 )  to  th e  s ta te  o r  lo ca l 
h e a lth  d e p a r tm e n ts .
State  and  Local Health D epartm ents
S ta te  a n d  lo c a l h e a lth  d e p a r tm e n ts  a re  re q u e s te d  t o  in v e s t ig a te  cases o f  s u s p e c t o r  p ro b a b le  
C e ph -R  NG (see  case d e f in i t io n s ,  pa g e s  8 - 9 )  a n d  ta k e  a p p ro p r ia te  p u b lic  h e a lth  a c t io n , in c lu d in g  
e n s u r in g  th a t  se x  p a r tn e rs  o f  c a s e -p a t ie n ts  a re  te s te d  u s in g  c u l tu re  a n d  AST ( i f  c u ltu re  is 
p o s it iv e )  a n d  a re  a d e q u a te ly  t r e a te d  f o r  g o n o r rh e a  based  o n  th e  AST re s u lts  o f  th e  case - 
p a t ie n t 's  is o la te . H e a lth  d e p a r tm e n ts  a re  re q u e s te d  to  re p o r t  cases o f  s u s p e c t o r  p ro b a b le  
C e ph -R  NG to  CDC a t g is p in fo @ c d c .g o v  o r  (4 0 4 ) 6 3 9 -8 6 5 9 . S ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts  
a re  a lso  re q u e s te d  to  e n h a n c e  s u rv e illa n c e  fo r  C e ph -R  NG cases.
P o ss ib le  o p t io n s  f o r  e n h a n c in g  s u rv e illa n c e  in c lu d e :
•  M o n i to r in g  a n d  in v e s t ig a t in g  p a t ie n ts  w ith  m u lt ip le  la b o ra to ry  o r  c lin ic a l r e p o r ts  o f  N .  
g o n o r r h o e a e  in fe c t io n s  d o c u m e n te d  w ith in  th e  p re c e d in g  30  d a ys  o r  6 0  da ys , to  
d e te r m in e  w h e th e r  su ch  re p o r ts  a re  d u p l ic a t iv e ,  re - in fe c t io n s ,  o r  c e p h a lo s p o r in  
t r e a tm e n t  fa i lu re s , a n d  fo l lo w in g  u p  w ith  p o s s ib le  t r e a tm e n t  fa i lu re s  to  o b ta in  a te s t  o f  
c u re
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•  S tre n g th e n in g  o f  lo ca l c u ltu re  a n d  AST c a p a c ity  a n d  access  (see E x p a n s i o n  o f  C u l t u r e  a n d  
A S T  C a p a c i t y ,  pag e  10)
•  R o u t in e ly  re v ie w in g  lo c a l N . g o n o r r h o e a e  AST re s u lts  ( i f  a v a ila b le )  f r o m  th e  lo ca l p u b lic  
h e a lth  la b o ra to ry  o r  c o m m e rc ia l la b o ra to r ie s  d o in g  AST. R e p o r t in g  o f  AST re s u lts  has 
b e e n  s u c c e s s fu lly  m a n d a te d  in a t  le a s t o n e  ju r is d ic t io n ,  a n d  s a m p le  re g u la to ry  la n g u a g e  
is a v a ila b le  (see  A p p e n d i x  II, pag e  2 3 ).
•  Im p le m e n t in g  ro u t in e  te s t  o f  c u re  f o r  p a t ie n ts  w it h  g o n o r rh e a  fo r  p ro s p e c t iv e  case 
f in d in g  o f  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re s
•  E s ta b lis h in g  a lo ca l g o n o c o c c a l s u s c e p t ib i l i ty  s u rv e illa n c e  s y s te m  in a fe w  c lin ic s  w ith  a 
h ig h  v o lu m e  o f  g o n o r rh e a  cases
CDC
CDC w il l  c o n t in u e  to  c o n d u c t  s e n t in e l s u rv e illa n c e  o f  a n t im ic ro b ia l  s u s c e p t ib i l i ty  th r o u g h  GISP; 
d is s e m in a te  s u rv e illa n c e  d a ta ; p ro v id e  s u rv e illa n c e , e p id e m io lo g ic a l,  la b o ra to ry ,  c lin ic a l a n d  
p ro g ra m m a t ic  te c h n ic a l a s s is ta n c e  re s o u rc e s  a n d  to o ls  to  s ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts ;  
u p d a te  t r e a tm e n t  re c o m m e n d a t io n s ;  p ro v id e  t r a in in g  a n d  te c h n ic a l a s s is ta n c e  re s o u rc e s  a n d  
to o ls  o n  c u ltu re  a n d  AST te c h n iq u e s  to  c lin ic ia n s  a n d  la b o ra to r ia n s ;  a n d  a c t as a re fe re n c e  
la b o ra to r y  f o r  c o n f i r m a to r y  s u s c e p t ib i l i ty  te s t in g .  CDC w il l  a lso  w o rk  w ith  p a r tn e rs  to  e v a lu a te  
a n d  re c o m m e n d  N . g o n o r r h o e a e  t r a n s p o r t  m e d ia ; p ro v id e  re fe re n c e  s tra in  p a n e ls  to  
la b o ra to r ie s  fo r  AST q u a l i t y  a s s u ra n c e ; e v a lu a te  a n d  d e f in e  th e  E te s t a n d  d is k  d if fu s io n  re s u lts  
t h a t  a re  c o m p a ra b le  to  th e  a g a r d i lu t io n  M IC  b re a k p o in ts  lis te d  in th e  S u s p e c t a n d  P ro b a b le  
C e ph -R  NG Case D e f in it io n s  (p a g e s  8 - 9 ) ;  e v a lu a te  o p t im a l te s t  o f  c u re  a lg o r ith m s ; a n d  w il l  
c o n t in u e  to  c o l la b o ra te  w it h  in te rn a t io n a l p a r tn e rs  to  e n h a n c e  a n d  s tr e n g th e n  g lo b a l 
s u rv e illa n c e  a n d  c o m m u n ic a t io n  o f  g o n o c o c c a l re s is ta n c e .
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W o r k i n g  C a s e  D e f i n i t i o n s  f o r  C e p h - R  N G
T h e  w o rk in g  case d e f in i t io n s  f o r  C eph -R  NG in fe c t io n  a re  based  o n  c lin ic a l e v id e n c e  o f  
c e p h a lo s p o r in  t r e a tm e n t  fa i lu re  a n d /o r  la b o ra to ry -b a s e d  AST re s u lts .
M a n y  c lin ic ia n s  d o  n o t  h a ve  access  to  AST a n d , th u s , th e  la b o ra to ry  c r i te r ia  m a y  n o t  be 
a p p lic a b le . H o w e v e r , la b o ra to r y  c r i te r ia  a re  in c lu d e d  s in c e  la b o ra to ry  d a ta  w i t h o u t  c lin ic a l 
o u tc o m e  d a ta  m a y  be a v a ila b le  in  s o m e  in s ta n c e s , su ch  as GISP is o la te s . D e fin in g  la b o ra to ry  
c r i te r ia  f o r  C eph -R  NG in fe c t io n  is c h a lle n g in g , s in ce  th e  C lin ic a l a n d  L a b o ra to ry  S ta n d a rd s  
In s t i tu te  (CLSI) has n o t  d e f in e d  M IC  b re a k p o in ts  f o r  re s is ta n c e  [2 6 ] . F u r th e rm o re ,  s in ce  
c e p h a lo s p o r in  t r e a tm e n t  fa i lu re s  h a ve  n o t  b e e n  re p o r te d  y e t  in  th e  U n ite d  S ta te s , w e  la ck  a 
c le a r  u n d e rs ta n d in g  o f  th e  re la t io n s h ip  b e tw e e n  M IC  b re a k p o in ts  a n d  l ik e lih o o d  o f  t r e a tm e n t  
fa i lu re .  T h e  M IC  b re a k p o in ts  f o r  c e f ix im e  used  in th e  case  d e f in i t io n s  b e lo w  d i f fe r  f r o m  th e  
b re a k p o in ts  f o r  c e f t r ia x o n e  b e c a u s e  c e f ix im e  M IC s  a re  g e n e ra l ly  o n e -d i lu t io n  h ig h e r  th a n  
c e f t r ia x o n e  M IC s.
T h e  la b o ra to r y  c r i te r ia  in  th is  d o c u m e n t re fe r  to  c e p h a lo s p o r in  M IC s  o b ta in e d  b y  th e  a g a r 
d i lu t io n  m e th o d . CDC is c u r r e n t ly  in  th e  p ro c e s s  o f  e v a lu a t in g  a n t im ic ro b ia l  s u s c e p t ib i l i ty  
re s u lts  o b ta in e d  b y  th e  E te s t a n d  d is k  d if fu s io n  m e th o d s , a n d  is w o rk in g  to  e s ta b lis h  E te s t a n d  
d is k  d if fu s io n  b re a k p o in ts  th a t  a re  e q u iv a le n t  to  th e  a g a r d i lu t io n  b re a k p o in ts  lis te d  b e lo w . 
U n t i l  th e s e  d a ta  a re  a v a ila b le , fa c i l i t ie s  u s in g  th e  E te s t m e th o d  s h o u ld  use th e  M IC  b re a k p o in ts  
l is te d  b e lo w  ( th e  s a m e  b re a k p o in ts  t h a t  a re  used  f o r  a g a r d i lu t io n ) .  F a c ilit ie s  u s in g  th e  d is k  
d if fu s io n  m e th o d  s h o u ld  use th e  s ta n d a rd s  p u b lis h e d  b y  th e  CLSI [2 6 ] (see  ta b le  in  A p p e n d i x  III, 
pa g e  2 4 ).
T h e s e  w o rk in g  case  d e f in i t io n s  a re  e x p e c te d  to  e v o lv e  as n e w  d a ta  b e c o m e  a v a ila b le .
Case Description
A  s e x u a lly  t r a n s m it te d  in fe c t io n  (STI) c a u se d  b y  a c e p h a lo s p o r in - re s is ta n t  s tra in  o f  N .  




A  s u s p e c t case fu l f i l ls  e i th e r  th e  c lin ic a l c r i te r ia  o r  la b o ra to r y  c r i te r ia  d e s c r ib e d  b e lo w :
S u s p e c t  C a s e :  C l in i c a l  C r i t e r i a
T h e  p a t ie n t  e x p e r ie n c e d  p o s s ib le  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re  ( s y m p to m a t ic  o r  
a s y m p to m a t ic )  w it h  th e  fo l lo w in g  s p e c if ic  c o m p o n e n ts :
•  P a t ie n t had  la b o ra to ry - c o n f i rm e d  N . g o n o r r h o e a e  in fe c t io n ,  a n d
•  P a t ie n t re c e iv e d  C D C -re c o m m e n d e d  c e p h a lo s p o r in -b a s e d  a n t im ic ro b ia l  re g im e n  as 
t r e a tm e n t ,  a n d
•  P a t ie n t s u b s e q u e n t ly  had  a p o s it iv e  N . g o n o r r h o e a e  te s t  re s u lt  (p o s it iv e  c u ltu re  > 7 2  
h o u rs  a f t e r  t r e a tm e n t  o r  p o s it iv e  N A A T  >7  d a ys  a f t e r  t r e a tm e n t ) ,  a n d
•  P a t ie n t d id  n o t  e n g a g e  in se xu a l a c t iv i ty  a f te r  t r e a tm e n t
OR
S u s p e c t  C a s e :  L a b o r a t o r y  C r i t e r i a
AST o f  p re - t r e a tm e n t  o r  p o s t - t r e a tm e n t  is o la te  o f  N . g o n o r r h o e a e  d e m o n s tra te s :
•  C e fix im e  M IC  > 0 .2 5  n g /m l,  o r
•  C e ftr ia x o n e  M IC  > 0 .1 2 5  n g /m l
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Probable Case
A  p ro b a b le  case fu l f i l ls  th e  c lin ic a l a n d  la b o ra to ry  c r i te r ia  d e s c r ib e d  b e lo w  o r  fu l f i l ls  th e  
e le v a te d  la b o ra to ry  c r i te r ia  d e s c r ib e d  b e lo w :
P r o b a b l e  C a s e :  C l in i c a l  C r i t e r i a  a n d  L a b o r a t o r y  C r i t e r i a
T h e  p a t ie n t  e x p e r ie n c e d  p o s s ib le  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re  ( s y m p to m a t ic  o r  
a s y m p to m a t ic )  w it h  th e  fo l lo w in g  s p e c if ic  c o m p o n e n ts :
•  P a t ie n t had  la b o ra to ry - c o n f irm e d  N . g o n o r r h o e a e  in fe c t io n ,  a n d
•  P a t ie n t re c e iv e d  C D C -re c o m m e n d e d  c e p h a lo s p o r in -b a s e d  a n t im ic ro b ia l  re g im e n  as
t r e a tm e n t ,  a n d
•  P a t ie n t s u b s e q u e n t ly  had  a p o s it iv e  N . g o n o r r h o e a e  te s t  re s u lt  (p o s it iv e  c u ltu re  > 7 2
h o u rs  a f t e r  t r e a tm e n t  o r  p o s it iv e  N A A T  >7  d a ys  a f t e r  t r e a tm e n t ) ,  a n d
•  P a t ie n t d id  n o t  e n g a g e  in se xu a l a c t iv i ty  a f te r  t r e a tm e n t
A N D
AST o f  p re - t r e a tm e n t  o r  p o s t - t r e a tm e n t  is o la te  o f  N . g o n o r r h o e a e  d e m o n s tra te s :
•  C e fix im e  M IC  > 0 .2 5  n g /m l,  o r
•  C e ftr ia x o n e  M IC  > 0 .1 2 5  n g /m l
OR
P r o b a b l e  C a s e :  E l e v a t e d  L a b o r a t o r y  C r i t e r i a
AST o f  p re - t r e a tm e n t  o r  p o s t - t r e a tm e n t  is o la te  o f  N . g o n o r r h o e a e  d e m o n s tra te s :
•  C e fix im e  M IC  > 0 .5  n g /m l,  o r
•  C e ftr ia x o n e  M IC  > 0 .2 5  n g /m l
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C h a l l e n g e s  t o  S u r v e i l l a n c e  f o r  C e p h - R  N G
T h e re  a re  o p e ra t io n a l d i f f ic u l t ie s  f o r  c lin ic ia n s , la b o ra to r ia n s  a n d  h e a lth  d e p a r tm e n ts  to  d e te c t  
s u s p e c t a n d  p ro b a b le  C e ph -R  NG cases. T h e  m a in  im p le m e n ta t io n  b a r r ie rs  in c lu d e :
•  E x is tin g  s u rv e illa n c e  s y s te m s  th a t  a re  n o t  l ik e ly  t o  be  s e n s it iv e  o r  t im e ly  e n o u g h  to  
d e te c t  in it ia l  e m e rg e n c e . F o r e x a m p le , as a s e n t in e l s u rv e illa n c e  s y s te m , GISP o n ly  
s a m p le s  a p p ro x im a te ly  4%  o f  m a le  u re th ra l g o n o r rh e a  m o r b id i ty  a n d  u s u a lly  ta k e s  
>1  m o n th  to  re tu rn  a c o n f irm e d  a b n o rm a l M IC  re s u lt  t o  th e  s e n t in e l c lin ic  s ite .
•  Lack o f  c l in ic ia n 's  a w a re n e s s  re g a rd in g  e m e rg in g  C e ph -R  NG
•  Lack o f  c l in ic ia n 's  t r a in in g  in th e  a p p ro p r ia te  c o l le c t io n  o f  c lin ic a l s a m p le s  s u ita b le  
f o r  c u ltu re  a n d  AST, a n d  la ck  o f  q u a l i t y  a s s u ra n c e  m o n ito r in g
•  Lack o f  c l in ic  a v a i la b i l i ty  o f  la b o ra to r y  s u p p lie s  a n d  p ro to c o ls /p ro c e d u re s  fo r  
c o l le c t io n  a n d  t r a n s p o r t  o f  c u ltu re  s p e c im e n s  ( i.e . s w a b , t r a n s p o r t  m e d iu m , c u ltu re  
p la te s , CO2 ta b le ts /c a n d le  ja rs  a n d  in c u b a to rs )
•  L im ite d  a v a i la b i l i ty  o f  la b o ra to r y  s e rv ic e s  f o r  g o n o c o c c a l c u l tu re  a n d  AST a t  th e  
c lin ic a l la b o ra to r ie s
•  Lack o f  m a n d a to ry  la b o ra to ry  re p o r t in g  o f  g o n o c o c c a l AST re s u lts  to  th e  lo c a l, s ta te , 
a n d  n a t io n a l p u b lic  h e a lth  a u th o r it ie s
•  D e c lin in g  n a t io n a l,  s ta te  a n d  lo ca l STI c o n tro l re s o u rc e s , p e rs o n n e l a n d  fu n d in g
•  T e s t o f  c u re  is n o  lo n g e r  ro u t in e  s ta n d a rd  f o r  c a re  f o r  m a n a g e m e n t o f  g o n o r rh e a ,  so 
th a t  a s y m p to m a t ic  t r e a tm e n t  fa i lu re s  a re  u n l ik e ly  to  be  d e te c te d
•  L im ite d  d a ta  o n  th e  e x p e c te d  d u ra t io n  o f  N A A T -p o s it iv ity  a f te r  s u c c e s s fu l t r e a tm e n t
•  In a d e q u a te  d a ta  o n  th e  c o m p a r a b i l i t y  o f  a g a r d i lu t io n ,  E te s t, a n d  d is k  d if fu s io n  fo r  
AST
E x p a n s i o n  o f  C u l t u r e  a n d  A S T  C a p a c i t y
T h e  re d u c t io n  o f  c u ltu re  a n d  AST c a p a b il i ty  in  th e  m a n y  c lin ic a l la b o ra to r ie s  is a c h a lle n g e  to  
a c h ie v in g  t im e ly  a n d  e f fe c t iv e  m o n ito r in g  o f  C eph -R  NG . N A A T  is n o w  th e  s ta n d a rd  o f  c a re  f o r  
N . g o n o r r h o e a e  d ia g n o s is , a n d  th e  a v a i la b i l i ty  o f  ro u t in e  c u ltu re s  a n d  AST f o r  N . g o n o r r h o e a e  is 
in c re a s in g ly  l im ite d ,  e s p e c ia lly  f o r  th e  in c re a s in g  p ro p o r t io n  o f  p a t ie n ts  se e n  in s e tt in g s  o th e r  
th a n  an  STD c lin ic . In  m o s t c lin ic s , s u p p lie s  a n d  p ro p e r  c o n d it io n s  f o r  g o n o c o c c a l c u ltu re  
s p e c im e n  c o l le c t io n  (d ire c t  in o c u la t io n  o n to  s e le c tiv e  o r  n o n -s e le c t iv e  m e d ia ) , s to ra g e , a n d  
t r a n s p o r t  (an  a tm o s p h e re  s u p p le m e n te d  w ith  CO2 a n d  m a in ta in e d  a t  3 5 - 3 7 oC) a re  n o t 
a v a ila b le . A ccess  to  t r a n s p o r t  m e d ia  th a t  a d e q u a te ly  m a in ta in s  th e  v ia b i l i t y  o f  N . g o n o r r h o e a e  
u n t i l  th e  s p e c im e n  re a c h e s  a la b o ra to r y  n e e d s  to  be  e s ta b lis h e d  fo r  c lin ic ia n s , e s p e c ia lly  th o s e
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w o rk in g  in  F e d e ra lly  Q u a lif ie d  H e a lth  C e n te rs , p r im a ry  c a re , H IV  c a re , c o r re c t io n s  fa c i l it ie s ,  a n d  
o th e r  c lin ic a l s e tt in g s  s e rv in g  a d o le s c e n ts , y o u n g  a d u lts ,  a n d  M S M  a t  h ig h  r is k  f o r  g o n o r rh e a .
A  s tra te g ic  a p p ro a c h  to  e x p a n s io n  o f  c u ltu re  a n d  AST c a p a c ity  is re q u ire d  to  s u p p o r t  th e  
p ro p o s e d  e n h a n c e d  s u rv e illa n c e  a n d  re s p o n s e  a c t iv i t ie s  f o r  C e ph -R  NG . T h e  s tra te g y  s h o u ld  
in c lu d e :
A t  s ta te  a n d  lo c a l h e a lth  d e p a r tm e n ts :
•  Loca l a s s e s s m e n t b y  h e a lth  d e p a r tm e n ts  o f  c o m m e rc ia l a n d  p u b lic  h e a lth  la b o ra to ry  
c a p a c ity  in  g o n o c o c c a l c u l tu re  a n d  AST
•  In lo c a le s  t h a t  la ck  c u ltu re  a n d  AST c a p a b il i t ie s ,  e s ta b l is h m e n t o f  p a r tn e rs h ip s  w ith  
la b o ra to r ie s  th a t  can  p ro v id e  c u ltu re  a n d  AST. T h e se  p a r tn e rs h ip s  m a y  in c lu d e  th e  
e s ta b l is h m e n t o f  lo c a l, s ta te , o r  re g io n a l n e tw o rk s  to  s u p p o r t  c u ltu re  a n d  AST.
•  Loca l h e a lth  d e p a r tm e n t  fa c i l i t a t io n  o f  access  to  g o n o c o c c a l c u ltu re ,  e s p e c ia lly  in  c lin ic s  
s e rv in g  p a t ie n ts  a t  r is k  f o r  g o n o r rh e a  o r  f r o m  w h e re  a h ig h  v o lu m e  o f  g o n o r rh e a  cases 
a re  re p o r te d ,  e i th e r  th r o u g h  d e v e lo p in g  re fe r ra l s y s te m s  w ith  d o c u m e n te d  lin k a g e  to  
c u l tu re  f o r  lo ca l c lin ic ia n s , o r  fa c i l i t a t io n  o f  lo ca l a v a i la b i l i ty  o f  N . g o n o r r h o e a e  c u ltu re  
p la te s , t r a n s p o r t  m e d ia  a n d  a p p ro p r ia te  t r a n s p o r t  s u p p lie s  to  c lin ic ia n s
•  F a c il ita t io n  o f  lo c a l t r a in in g  f o r  c lin ic ia n s  a n d  la b o ra to r ia n s
A t  CDC:
•  A s s is t w ith  a s s e s s m e n t o f  s ta te  a n d  lo c a l h e a lth  d e p a r tm e n t  access  to  g o n o c o c c a l 
c u l tu re  a n d  AST
•  E v a lu a t io n  o f  e x is t in g  t r a n s p o r t  m e d ia  (e .g ., A m ie s  c h a rc o a l,  T ra n s g ro w , InT ray™ ) a n d  
id e n t i f ic a t io n  o r  d e v e lo p m e n t  o f  t r a n s p o r t  m e d ia  t h a t  m a in ta in  N . g o n o r r h o e a e  v ia b i l i t y  
a n d  th a t  can  be used  in  th e  n o n -S T D  c lin ic  s e t t in g  o r  in  o th e r  c l in ic  s e tt in g s  w h e re  
a p p ro p r ia te  c u ltu re  p la te s , c a n d le  ja rs , a n d  in c u b a to rs  a re  n o t  a v a ila b le
•  D e v e lo p m e n t o f  t r a in in g  a n d  te c h n ic a l a s s is ta n c e  re s o u rc e s  (w e b s ite  m a te r ia ls , 
p ro to c o ls ,  a n d  m a n u a ls )  o n  s p e c im e n  c o l le c t io n ,  t r a n s p o r t ,  c u ltu re  &  AST te c h n iq u e s  
a n d  im p le m e n ta t io n  o f  w e b s ite -b a s e d  t r a in in g  a c t iv it ie s ,  in  c o l la b o ra t io n  w ith  p u b lic  
(e .g . A s s o c ia t io n  o f  P u b lic  H e a lth  L a b o ra to r ie s )  a n d  p r iv a te  s e c to r  p a r tn e rs  (e .g ., Q u e s t, 
La b C o rp , a n d  K a ise r)
A t  th is  t im e ,  th e  m o le c u la r  m e c h a n is m s  a s s o c ia te d  w ith  c e p h a lo s p o r in  re s is ta n c e  h a ve  n o t  
b e e n  fu l ly  e lu c id a te d .  L a b o ra to ry  s tu d ie s  to  im p ro v e  o u r  k n o w le d g e -b a s e  o f  m o le c u la r  a n d  
b io lo g ic  m e c h a n is m s  o f  re s is ta n c e  s h o u ld  be  c o n t in u e d  a n d  m ig h t  c o n t r ib u te  to  th e  
d e v e lo p m e n t  o f  m o le c u la r  d e te c t io n  m e th o d s  fo r  re s is ta n t o rg a n is m s . A  p o in t-o f - c a re
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m o le c u la r  te s t  f o r  d e te c t io n  o f  re s is ta n c e  w o u ld  d ra m a t ic a lly  e n h a n c e  o u r  n a t io n a l re s p o n s e  to  
c e p h a lo s p o r in  re s is ta n t a n d  m u lt i - d ru g  re s is ta n t g o n o r rh e a .
R e c o m m e n d e d  C l i n i c a l  M a n a g e m e n t  a n d  P u b l i c  H e a l t h  
R e s p o n s e  F o l l o w i n g  D e t e c t i o n  o f  S u s p e c t  o r  P r o b a b l e  
C e p h - R  N G
Clinician Responsibilities
C e fix im e  t r e a tm e n t  fa i lu re s .  W h e n  a c l in ic ia n  id e n t i f ie s  a p a t ie n t  w ith  g o n o r rh e a  a n d  p o s s ib le  
t r e a tm e n t  fa i lu re  (see  D e t e c t i n g  p o s s i b l e  c e p h a l o s p o r i n  t r e a t m e n t  f a i l u r e ,  pa g e  4 ) fo l lo w in g  
t r e a tm e n t  w ith  an  o ra l c e p h a lo s p o r in  ( i.e ., c e f ix im e ) ,  h e /s h e  s h o u ld :
•  B ased o n  a n a to m ic  e x p o s u re  h is to ry ,  o b ta in  s p e c im e n s  f o r  c u ltu re  f r o m  p h a ry n g e a l, 
re c ta l,  a n d  g e n ita l s ite s  f o r  AST. C lin ic ia n s  s h o u ld  n o t i f y  th e  la b o ra to r y  th a t  th e  
s p e c im e n  w a s  o b ta in e d  f r o m  a p a t ie n t  w ith  p o s s ib le  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re .
•  R e - tre a t w ith  2 5 0  m g  o f  c e f t r ia x o n e  as a s in g le  in t ra m u s c u la r  d o s e  a n d  a z ith ro m y c in  2 
g ra m s  o ra l ly  as a d u a l th e r a p y
•  E n su re  e ra d ic a t io n  o f  in fe c t io n  w ith  a te s t  o f  c u re  a f t e r  re - t r e a tm e n t ,  p re fe ra b ly  w ith  
c u l tu re  (> 7 2  h o u rs  a f te r  re - t r e a tm e n t ) ,  o r  i f  c u ltu re  is n o t  a v a ila b le , w ith  N A A T  (>7  d a ys  
a f t e r  re - t r e a tm e n t ) .  I f  th e  te s t  o f  c u re  N A A T  is p o s it iv e , a s p e c im e n  f o r  c u ltu re  s h o u ld  
be  o b ta in e d  to  b o th  e n s u re  th a t  th e  N A A T  re s u lt  is re l ia b le  f o r  a c t iv e  in fe c t io n  a n d  to  
a l lo w  fo r  AST.
•  T e s t th e  p a t ie n t 's  sex  p a r tn e rs  f r o m  th e  tw o  m o n th s  p re c e d in g  th e  p a t ie n t 's  in it ia l  
g o n o r rh e a  d ia g n o s is  d a te  (p r e fe ra b ly  w ith  c u ltu re  f r o m  a ll e x p o s e d  s ite s ) a n d  e m p ir ic a lly  
t r e a t  th e s e  p a r tn e rs  w ith  c e f t r ia x o n e  2 5 0  m g  in tra m u s c u la r ly  a n d  a z ith ro m y c in  2 g ra m s  
o ra l ly  as d u a l th e r a p y
•  P ro m p t ly  n o t i f y  th e  s ta te  o r  lo ca l h e a lth  d e p a r tm e n ts  w ith in  24  h o u rs  o f  id e n t i f ic a t io n
C e f t r ia x o n e  t r e a tm e n t  fa i lu re s .  W h e n  a c l in ic ia n  id e n t i f ie s  a p a t ie n t  w ith  g o n o r rh e a  a n d  
p o s s ib le  t r e a tm e n t  fa i lu re  (see D e t e c t i n g  p o s s i b l e  c e p h a l o s p o r i n  t r e a t m e n t  f a i l u r e ,  page  4 ) 
fo l lo w in g  t r e a tm e n t  w ith  an  in je c ta b le  c e p h a lo s p o r in  ( i.e ., c e f t r ia x o n e ) ,  h e /s h e  s h o u ld :
•  C o n s u lt w ith  a lo ca l in fe c t io u s  d ise a se s  e x p e r t  o r  S T D /H IV  P re v e n t io n  T ra in in g  C e n te r  
(see  w w w .n n p tc .o r g  f o r  re g io n a l c o n ta c t  in fo rm a t io n ) ,  a n d  w ith  th e  s ta te  o r  lo ca l h e a lth  
d e p a r tm e n t ,  re g a rd in g  r e - t r e a tm e n t  a n d  p a r tn e r  m a n a g e m e n t.  T h e  s ta te  o r  lo ca l h e a lth  
d e p a r tm e n ts  s h o u ld  in fo rm  CDC.
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•  B ased o n  a n a to m ic  e x p o s u re  h is to ry ,  o b ta in  s p e c im e n s  f o r  c u ltu re  f r o m  p h a ry n g e a l, 
re c ta l,  a n d  g e n ita l s ite s  f o r  AST. C lin ic ia n s  s h o u ld  n o t i f y  th e  la b o ra to r y  th a t  th e  
s p e c im e n  w a s  o b ta in e d  f r o m  a p a t ie n t  w ith  p o s s ib le  c e p h a lo s p o r in  t r e a tm e n t  fa i lu re .
•  E n su re  e ra d ic a t io n  o f  in fe c t io n  w ith  a te s t  o f  c u re  a f t e r  re - t r e a tm e n t ,  p re fe ra b ly  w ith  
c u l tu re  (> 7 2  h o u rs  a f te r  r e - t r e a tm e n t) ,  o r  i f  c u ltu re  is n o t  a v a ila b le , w it h  N A A T  (> 7  d a ys  
a f t e r  re - t r e a tm e n t ) .  I f  th e  te s t  o f  c u re  N A A T  is p o s it iv e , a s p e c im e n  f o r  c u ltu re  s h o u ld  
be  o b ta in e d  to  b o th  e n s u re  th a t  th e  N A A T  re s u lt  is re l ia b le  f o r  a c t iv e  in fe c t io n  a n d  to  
a l lo w  f o r  AST.
•  T e s t th e  p a t ie n t 's  sex  p a r tn e rs  f r o m  th e  tw o  m o n th s  p re c e d in g  th e  p a t ie n t 's  in it ia l  
g o n o r rh e a  d ia g n o s is  d a te  (p r e fe ra b ly  w ith  c u ltu re  f r o m  a ll e x p o s e d  s ite s ) a n d  e m p ir ic a lly  
t r e a t  th e s e  p a r tn e rs  w ith  th e  s a m e  a n t im ic ro b ia l  re g im e n  w ith  w h ic h  th e  in d e x  p a t ie n t  
w a s  re - t re a te d  a n d  w h ic h  m o s t l ik e ly  w i l l  c u re  h im /h e r  (b a se d  o n  c o n s u lta t io n  w ith  a 
lo c a l in fe c t io u s  d ise a se  e x p e r t ,  s ta te  o r  lo ca l h e a lth  d e p a r tm e n t ,  a n d  CDC)
•  P ro m p t ly  n o t i f y  th e  s ta te  o r  lo ca l h e a lth  d e p a r tm e n t  w ith in  2 4  h o u rs  o f  id e n t i f ic a t io n
Laboratorian Responsibilities
L a b o ra to r ia n s  w h o  id e n t i fy  a N . g o n o r r h o e a e  is o la te  w ith  AST re s u lts  t h a t  a re  c o n s is te n t w ith  
s u s p e c t o r  p ro b a b le  C eph -R  NG (see Case D e f in it io n s , pa g e s  8 - 9 )  s h o u ld  p r o m p t ly  n o t i f y  (w ith in  
2 4  h o u rs )  th e  o rd e r in g  c l in ic ia n  as w e ll as th e  s ta te  o r  lo ca l h e a lth  d e p a r tm e n t .  R e su lts  f r o m  
is o la te s  a s s o c ia te d  w ith  p o s s ib le  c lin ic a l t r e a tm e n t  fa i lu re s  s h o u ld  a lso  be  p r o m p t ly  r e p o r te d .  
C u ltu re  s p e c im e n s  o b ta in e d  f r o m  a ll p a t ie n ts  w ith  p o s s ib le  t r e a tm e n t  fa i lu re  o r  s u s p e c t o r  
p ro b a b le  C eph -R  NG in fe c t io n  s h o u ld  be  s e n t to  CDC f o r  AST b y  a g a r d i lu t io n  a n d  s to re d  a t th e  
lo c a l la b o ra to r y  a n d /o r  CDC in  case fu r t h e r  te s t in g  is n e e d e d .
T e s tin g  a n d /o r  s to ra g e  o f  s p e c im e n s  o r  is o la te s  a t CDC s h o u ld  be  fa c i l i ta te d  b y  th e  s ta te  o r  lo ca l 
h e a lth  d e p a r tm e n t  a c c o rd in g  t o  lo c a l p u b lic  h e a lth  p ro to c o ls .  In s t ru c t io n s  f o r  s h ip p in g  is o la te s  
t o  CDC can  be  fo u n d  a t:
w w w .c d c .g o v /s td /G o n o r rh e a /a rg /s p e c im e n _ s h ip p in g _ in s t ru c t io n s 1 -2 9 -0 8 .p d f  
N . g o n o r r h o e a e  is c la s s if ie d  as C a te g o ry  B (U N  3 3 7 3 ).
State  and Local Health D epartm ent Responsibilities
W h e n  n o t i f ie d  b y  a c l in ic ia n  o r  la b o ra to r ia n  o f  g o n o r rh e a  case w ith  p o s s ib le  t r e a tm e n t  fa i lu re  
o r  w ith  s u s p e c t o r  p ro b a b le  C e ph -R  NG in fe c t io n ,  lo c a l p u b lic  h e a lth  a u th o r it ie s  s h o u ld  in it ia te  
an  in v e s t ig a t io n  to  c o l le c t  th e  c lin ic a l a n d  e p id e m io lo g ic a l in fo rm a t io n  o u t l in e d  in  th e  I n t e r v i e w  
R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a  (see  A p p e n d i x  IV , pa g e  2 5 , o r  
h t tp : / /w w w .c d c .g o v /s td /P ro g ra m /fo r m s /G C _ C T _ I  R _ 6 _ 0 5 _ 2 0 0 8 .p d f a n d
h t tp : / /w w w .c d c .g o v /s td /P ro g ra m /fo rm s /G C -C T /G C _ C T - IR In s tru c t io n s .p d f  f o r  in s tru c t io n s )  f r o m  
th e  in d e x  case  a n d  s e xu a l p a r tn e r (s ) .  L o c a lly  d e v e lo p e d  in te r v ie w  in s tru m e n ts  t h a t  c o lle c t
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th e s e  d a ta  can  be u se d . D a ta  e le m e n ts  t h a t  s ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts  s h o u ld  c o n s id e r  
c o l le c t in g  d u r in g  an  in v e s t ig a t io n  a re  o u t l in e d  b e lo w , a n d  h e a lth  d e p a r tm e n ts  s h o u ld  a im  to  
g a th e r  th e s e  d a ta  w ith in  30  d a ys  o f  th e  id e n t i f ic a t io n  o f  a case . S ta te  a n d  lo ca l h e a lth  
d e p a r tm e n ts  a re  re q u e s te d  to  p r o m p t ly  n o t i f y  ( w ith in  2 4  h o u rs )  CDC 's D iv is io n  o f  STD 
P re v e n t io n  (a t (4 0 4 ) 6 3 9 -8 6 5 9  o r  g is p in fo @ c d c .g o v ) o f  s u s p e c t o r  p ro b a b le  C eph -R  NG cases 
(see  case  d e f in i t io n s ,  pages 8 - 9 ) ,  o r  i f  th e r e  is c o n c e rn  a b o u t  C e p h -N G  in fe c t io n  in a p a t ie n t  
w h o  d o e s  n o t  m e e t th e  case  d e f in i t io n .
Epidemiological Investigation of Suspect or Probable Ceph-R NG Cases
A ll cases a n d  se x  p a r tn e rs  w h o  can  be  tra c e d  s h o u ld  be  in te rv ie w e d  t o  id e n t i fy  th e  
d e m o g ra p h ic  c h a ra c te r is t ic s ,  se x u a l b e h a v io r ,  a n d  r is k  fa c to rs  o u t l in e d  o n  th e  I n t e r v i e w  R e c o r d  
f o r  G o n o r r h e a / C h l a m y d i a  (see  A p p e n d i x  IV , pag e  2 5 , o r
w w w .c d c .g o v /s td /P ro g ra m /fo rm s /G C _ C T _ IR _ 6 _ 0 5 _ 2 0 0 8 .p d f). Id e a lly , o th e r  p e rs o n s  w ith in  th e  
p a t ie n t 's  s o c io -s e x u a l n e tw o rk  s h o u ld  be  in te rv ie w e d  a lso .
T h e  I n t e r v i e w  R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a  in c lu d e s  th e  fo l lo w in g  d a ta  e le m e n ts  f o r  cases:
•  A g e , sex  a t b ir th ,  ra ce , a n d  e th n ic i ty
•  A d d re s s  o f  re s id e n c e , c o n ta c t  in fo rm a t io n
•  P ro v id e r  a n d  fa c i l i t y  ty p e  w h e re  te s te d
•  D a te (s ) o f  te s t(s ) , ty p e  o f  te s t(s ) , s o u rc e (s ) o f  s p e c im e n (s )  (a n a to m ic  s ite ) , a n d  re s u lt  o f  
te s t(s )
•  T re a tm e n t  d a te (s ) , d ru g (s ) a n d  d o s a g e (s ) g iv e n
•  G e n d e r  o f  sex  p a r tn e rs  in  la s t 12  m o n th s
•  H is to ry  o f  a n o n y m o u s  sex  in  th e  la s t 12  m o n th s
•  H is to ry  o f  in c a rc e ra t io n  in  th e  la s t 12  m o n th s
•  H is to ry  o f  in je c t io n  o r  n o n - in je c t io n  d ru g  use in th e  la s t 12  m o n th s
•  M e th o d  o f  case d e te c t io n ,  re a s o n  f o r  s e e k in g  ca re
•  H IV  s ta tu s
•  H is to ry  o f  s ig n s  o r  s y m p to m s
•  STD h is to ry
•  T y p e  o f  p a r tn e r  s e rv ic e s  o f fe re d  a n d  p ro v id e d
•  P lace  w h e re  p a t ie n t  m e t h is /h e r  p a r tn e r (s )
•  In c id e n ta l a n t im ic ro b ia l  t r e a tm e n t  in  th e  la s t 12  m o n th s , t r e a tm e n t  d a te s , d ru g  a n d  
d o s a g e , a n d  re a s o n  f o r  use
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In a d d it io n ,  i t  is re c o m m e n d e d  th a t  s ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts  c o l le c t  th e  fo l lo w in g  
d a ta  e le m e n ts  d u r in g  in te rv ie w s  w ith  a s u s p e c t o r  p ro b a b le  C e ph -R  NG case a n d  p a r tn e r (s )  a n d  
m e d ic a l re c o rd  re v ie w :
•  T y p e  o f  sex  (o ra l,  v a g in a l,  a n d /o r  a n a l; in s e r t iv e  a n d /o r  re c e p t iv e )
•  T ra v e l h is to ry  d u r in g  p a s t 3 m o n th s  ( in c lu d in g  p la ce  a n d  w h e th e r  th e  p a t ie n t  had  sex 
d u r in g  t r a v e l)
•  T ra v e l h is to ry  o f  sex  p a r tn e rs  in  th e  p a s t 3 m o n th s  ( i f  k n o w n )  ( in c lu d in g  p la ce  a n d  
w h e th e r  th e  p a r tn e r  had  sex  d u r in g  t r a v e l)
•  R e su lts  o f  AST ( i f  a v a ila b le  a n d  p e r fo rm e d )
•  H is to ry  o f  c o m m e rc ia l sex  w o rk  ( in v o lv e m e n t  in  o r  s o l ic i ta t io n  o f)
•  In c a rc e ra t io n  o f  sex  p a r tn e rs
B e lo w  a re  a d d it io n a l e p id e m io lo g ic a l a n d  d e s c r ip t iv e  in v e s t ig a t io n s  to  c o n s id e r  i f  a C eph -R  NG 
case is id e n t i f ie d  a n d  i f  lo ca l c a p a c ity  e x is ts . CDC can  p ro v id e  te c h n ic a l a s s is ta n c e  f o r  such  
in v e s t ig a t io n s .
E v a lu a te  e p id e m io lo g ic a l  c h a ra c te r is t ic s  a s s o c ia te d  w i t h  C e p h -R  N G  s tra in s :
•  C a s e -c o n tro l s tu d y  c o m p a r in g  d e m o g ra p h ic  a n d  r is k  b e h a v io rs  b e tw e e n  C e ph -R  NG 
cases a n d  c e p h a lo s p o r in -s u s c e p t ib le  cases
•  G e o s p a t ia l a n a ly s is  o f  cases
E v a lu a te  e p id e m io lo g ic a l  o r  n e tw o r k  l in k a g e s  b e tw e e n  cases :
•  In te r v ie w  in d e x  cases, sex  p a r tn e rs , a n d  se x  p a r tn e rs  o f  p a r tn e rs  to  e s ta b lis h  n e tw o rk  
lin k a g e s  o f  p e o p le  a n d  p la c e s /v e n u e s / in te r n e t  s ite s /s m a r t - p h o n e  a p p s
•  C o n d u c t s t ra in  ty p in g  o f  is o la te s  t o  assess m ic ro b io lo g ic a l lin k a g e s .
E v a lu a t io n  o f  e s t im a te d  lo c a l p re v a le n c e  o f  C e p h -R  N G :
•  R e v ie w  c a s e -b a s e d  s u rv e illa n c e  d a ta  to  id e n t i fy  re p e a t in fe c t io n s  in a s in g le  p e rs o n  
w ith in  a s h o r t  t im e  f r a m e  (e .g ., w i th in  p re c e d in g  30  to  60  d a ys )
•  Assess lo c a l AST c a p a c ity  a n d  re v ie w  lo ca l AST re s u lts
•  S y s te m a t ic a lly  c o l le c t  lo ca l s p e c im e n s  f o r  c u ltu re  a n d  AST
•  Im p le m e n t  r o u t in e  te s t  o f  c u re  f o r  p ro s p e c t iv e  lo ca l s u rv e illa n c e  f o r  C eph -R  NG cases
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G u i d a n c e  o n  T e s t  o f  C u r e
P a tie n ts  t r e a te d  f o r  g o n o r rh e a  w h o  (1 ) h a v e  s y m p to m s  w h ic h  fa i l  t o  re s o lv e  w ith in  3 -5  d a ys  
a f t e r  a p p ro p r ia te  t r e a tm e n t ,  (2 ) a re  fo u n d  to  h a ve  AST re s u lts  c o n s is te n t w ith  th e  la b o ra to ry  
c r i te r ia  f o r  s u s p e c t o r  p ro b a b le  C e ph -R  NG (see  case d e f in i t io n s ,  pa g e s  8 - 9 ) ,  (3 ) a re  t r e a te d  
w ith  an  a lte rn a t iv e  re g im e n  ( i.e ., a re g im e n  o th e r  th a n  c e f t r ia x o n e  2 5 0  m g  in t ra m u s c u la r ly  p lu s  
e i th e r  a z ith ro m y c in  1 g m  o ra l ly  as a s in g le  d o s e  o r  d o x y c y c lin e  1 0 0  m g  o ra l ly  tw ic e  a d a y  f o r  7 
d a ys ) s h o u ld  re c e iv e  a te s t  o f  c u re .
In a d d it io n ,  i f  c lin ic ia n s  o r  h e a lth  d e p a r tm e n ts  a re  c o n c e rn e d  a b o u t  lo ca l e m e rg e n c e  o f  C eph -R  
NG ba se d  o n  a v a ila b le  lo ca l GISP a n d  e p id e m io lo g ic a l d a ta , th e y  m ig h t  c o n s id e r  im p le m e n t in g  
o r  re c o m m e n d in g  ro u t in e  te s t  o f  c u re  7 - 1 0  d a ys  a f t e r  t r e a tm e n t  f o r  a ll g o n o r rh e a  cases fo r  a 
p e r io d  o f  t im e  to  d e te r m in e  y ie ld .  R o u tin e  te s t  o f  c u re  m a y  a l lo w  fo r  ra p id  id e n t i f ic a t io n  o f  
t r e a tm e n t  fa i lu re s  a n d  p ro v id e  t im e ly  p re v a le n c e  e s t im a te s  o f  c e p h a lo s p o r in  re s is ta n c e .
I f  d o n e , te s t  o f  c u re  is p re fe ra b ly  p e r fo rm e d  w ith  c u ltu re  (> 7 2  h o u rs  a f te r  t r e a tm e n t ) ,  b u t  m a y  
be  p e r fo rm e d  w ith  N A A T  (> 7  d a ys  a f t e r  t r e a tm e n t ) ,  i f  c u ltu re  is n o t  a v a ila b le . T h e  p o s s ib il ity  o f  
fa ls e -p o s it iv it y  w ith  N A A T  as e a r ly  as 7 d a ys  a f t e r  t r e a tm e n t  is a c o n c e rn , b u t  is l ik e ly  to  be  lo w
[2 7 ] . H o w e v e r , f u r t h e r  s tu d y  o n  th e  fe a s ib i l i t y  a n d  c o s t-e f fe c t iv e n e s s  o f  th is  a p p ro a c h  is 
w a r ra n te d ,  a n d  th e  re c o m m e n d a t io n s  o n  t im in g  o f  te s t  o f  c u re  a re  e x p e c te d  to  e v o lv e  as n e w  
d a ta  b e c o m e  a v a ila b le . A t  p re s e n t , a s y m p to m a t ic  p a t ie n ts  w ith  a p o s it iv e  N A A T  o n  te s t  o f  c u re  
s h o u ld  be  c u ltu re d .  W h ile  a w a it in g  th e  c u ltu re  re s u lt ,  th e s e  p a t ie n ts  s h o u ld  be  m a n a g e d  
a c c o rd in g  to  c lin ic a l h is to ry  a n d  re p o r te d  i f  th e y  m e e t th e  c u r r e n t  c r i te r ia  f o r  a s u s p e c t o r  
p ro b a b le  C e ph -R  NG case  (see case d e f in i t io n s ,  pages  8 - 9 ) .
G u i d a n c e  o n  P a r t n e r  S e r v i c e s  a n d  M a n a g e m e n t  o f  P a r t n e r s  o f  
S u s p e c t e d  a n d  P r o b a b l e  C e p h - R  N G
P ro v id e rs  s h o u ld  d iscu ss  w ith  th e i r  p a t ie n ts  w h o  h a ve  s u s p e c t o r  p ro b a b le  C eph -R  NG in fe c t io n  
th e  c r it ic a l n e e d  f o r  t h e i r  sex  p a r tn e rs  to  s e e k  m e d ic a l e v a lu a t io n  a n d  t r e a tm e n t ,  a n d  th e  ro le  
o f  h e a lth  d e p a r tm e n t  a s s is ta n c e  re g a rd in g  lin k in g  p a r tn e rs  to  c a re  a n d  t r e a tm e n t .
C lin ic ia n s  a n d  h e a lth  d e p a r tm e n ts  s h o u ld  m a k e  s tre n u o u s  e f fo r t s  to  l in k  p a r tn e rs  to  ca re . 
P a r tn e rs  o f  p a t ie n ts  w ith  s u s p e c t o r  p ro b a b le  C eph -R  NG in fe c t io n  s h o u ld  be  p r io r i t iz e d  f o r  
D isease  In te r v e n t io n  S p e c ia lis t p a r tn e r  s e rv ic e s  b y  s ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts ,  a n d
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s h o u ld  be  p r io r i t iz e d  f o r  u rg e n t  c lin ic a l ca re  a t STD c lin ic s  o r  o th e r  s e tt in g s  so th e y  can  be 
te s te d  a n d  t r e a te d  a p p ro p r ia te ly .
A ll sex  p a r tn e rs  o f  s u s p e c t o r  p ro b a b le  C eph -R  NG cases f r o m  th e  tw o  m o n th s  p re c e d in g  th e  
in d e x  p a t ie n t 's  in it ia l  te s t  d a te  ( i.e ., d a te  o f  d ia g n o s is )  s h o u ld  be  te s te d  f o r  N . g o n o r r h o e a e  
in fe c t io n  (p re fe ra b ly  w ith  c u ltu re  f r o m  a ll e x p o s e d  a n a to m ic  s ite s ), a n d  e m p ir ic a lly  t r e a te d  as 
fo l lo w s :  Sex p a r tn e rs  o f  p a t ie n ts  w it h  p o s s ib le  c e f ix im e  t r e a tm e n t  fa i lu re  s h o u ld  be  t r e a te d  
w ith  2 5 0  m g  c e f t r ia x o n e  in t ra m u s c u la r ly  a n d  a z ith ro m y c in  2 g ra m s  o ra l ly  in a s in g le  d o s e . Sex 
p a r tn e rs  o f  p a t ie n ts  w ith  p o s s ib le  c e f t r ia x o n e  t r e a tm e n t  fa i lu re  s h o u ld  be  t r e a te d  w ith  th e  
s a m e  a n t im ic ro b ia l  re g im e n  w ith  w h ic h  th e  in d e x  p a t ie n t  w a s  re - t re a te d  a n d  w h ic h  m o s t l ik e ly  
w i l l  c u re  h im /h e r  (b a se d  o n  c o n s u lta t io n  w ith  a lo ca l in fe c t io u s  d ise a se  e x p e r t  o r  S T D /H IV  
P re v e n t io n  T ra in in g  C e n te r , s ta te  o r  lo c a l h e a lth  d e p a r tm e n t ,  a n d  CDC). A ll sex  p a r tn e rs  s h o u ld  
be  te s te d  a n d  re - t re a te d  as d e s c r ib e d  a b o v e , e v e n  i f  th e y  w e re  p re v io u s ly  t r e a te d  w ith  o ra l 
c e f ix im e .
S ta te  a n d  lo c a l h e a lth  d e p a r tm e n ts  a n d  CDC s h o u ld  c o n t in u e  to  e v a lu a te  th e  ro le  a n d  
a d v is a b i l i t y  o f  e x p e d ite d  p a r tn e r  th e r a p y  (EPT) a f t e r  th e  e m e rg e n c e  o f  C eph -R  NG . B ecause  
lo c a l s u s c e p t ib i l i ty  d a ta  is u n l ik e ly  to  be  c o lle c te d  s y s te m a tic a lly ,  d e c is io n -m a k in g  m a y  be based  
u p o n  re g io n a l GISP d a ta . E xposed  sex  p a r tn e rs  s h o u ld  be  in fo rm e d  th a t  d u a l th e r a p y  w ith  
c e f t r ia x o n e  a n d  e i th e r  a z ith ro m y c in  o r  d o x y c y c lin e  is th e  m o s t e f fe c t iv e  t r e a tm e n t  fo r  
g o n o r rh e a ,  a n d  s h o u ld  be  s tr o n g ly  a d v is e d  to  p re s e n t to  a c l in ic  f o r  d u a l t r e a tm e n t  th a t  
in c lu d e s  c e f t r ia x o n e . H o w e v e r , f o r  h e te ro s e x u a l p a t ie n ts  w ith  g o n o r rh e a  w h o s e  p a r tn e rs  a re  
u n l ik e ly  to  se e k  e v a lu a t io n  a n d  t r e a tm e n t ,  EPT u s in g  c e f ix im e  a n d  e i th e r  a z ith ro m y c in  o r  
d o x y c y c lin e  can  be c o n s id e re d . T h is  a p p ro a c h  s h o u ld  a lw a y s  be  a c c o m p a n ie d  b y  e f fo r t s  to  
e n c o u ra g e  p a r tn e rs  to  se e k  c lin ic a l e v a lu a t io n  a n d  to  e d u c a te  p a r tn e rs  a b o u t th e  n e e d  f o r  te s t  
o f  c u re  i f  a c e f ix im e -b a s e d  re g im e n  is u sed .
M o n i t o r i n g  t h e  E f f e c t i v e n e s s  o f  t h e  C e p h - R  N G  R e s p o n s e  P l a n
S ta te  a n d  lo c a l h e a lth  d e p a r tm e n ts  s h o u ld  m o n i to r  th e  e ffe c t iv e n e s s  o f  C eph -R  NG re s p o n s e  
a c t iv i t ie s  b y  e s ta b lis h in g  s ta te  a n d  lo ca l p ro g ra m  im p ro v e m e n t  in d ic a to rs .  P o s it iv e  
im p ro v e m e n ts  c o u ld  be  in d ic a te d  by :
•  In c re a s e s  in  n u m b e r  o f  la b o ra to r ie s  w ith  N . g o n o r r h o e a e  c u l tu re  a n d  AST c a p a c ity
•  In c re a s e s  in  n u m b e r  o f  c lin ic s  w ith  a p p ro p r ia te  t r a n s p o r t  m e d ia  a n d  s p e c im e n  c o l le c t io n  
a n d  t r a n s p o r t  p ro c e d u re s
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•  Im p ro v e m e n ts  in  le v e l o f  a w a re n e s s  o n  th e  e m e rg e n c e  o f  C eph -R  NG a n d  re c o m m e n d e d  
p u b lic  h e a lth  re s p o n s e  a c t io n s  a m o n g  c lin ic ia n s  a n d  la b o ra to r ia n s
•  In c re a s e s  in  t im e ly  re p o r t in g  a n d  in v e s t ig a t io n  o f  s u s p e c t o r  p ro b a b le  C eph -R  NG cases
•  In c re a s e s  in  th e  p r o p o r t io n  o f  g o n o r rh e a  p a t ie n ts  t r e a te d  w ith  C D C -re c o m m e n d e d  
re g im e n : c e f t r ia x o n e  2 5 0  m g  in t ra m u s c u la r ly  p lu s  e i th e r  a z ith ro m y c in  1 g m  o ra l ly  as a 
s in g le  d o s e  o r  d o x y c y c lin e  1 0 0  m g  o ra l ly  tw ic e  a d a y  f o r  7 d a ys
•  O th e r  s u rv e illa n c e  s y s te m  in d ic a to rs  su ch  as s e n s it iv ity ,  s p e c if ic ity ,  t im e lin e s s  in 
d e te c t in g  s u s p e c t o r  p ro b a b le  C e ph -R  NG cases
CDC s h o u ld  assess th e  o v e ra ll im p a c t o f  n a t io n a l C e ph -R  NG p u b lic  h e a lth  re s p o n s e  a c t io n  b y  
m o n ito r in g  lo ca l access to  c u ltu re /A S T  a n d  th e  t r e n d s  o f  e m e rg e n c e  a n d  t ra n s m is s io n  o f  C eph-R  
NG s tra in s  in  th e  U n ite d  S ta te s  b y  u s in g  e p id e m io lo g y  a n d  m a th e m a t ic a l m o d e lin g  a p p ro a c h e s .
R o l e  o f  E n h a n c e d  G o n o r r h e a  P r e v e n t i o n  a n d  C o n t r o l  A c t i v i t i e s
W h ile  th e  c lin ic a l a n d  p u b lic  h e a lth  re s p o n s e s  re c o m m e n d e d  b y  th e  C eph -R  NG R e sp o nse  P lan 
la rg e ly  fo c u s  o n  ta rg e te d  in te r v e n t io n  a c t iv i t ie s  f o r  s u s p e c t o r  p ro b a b le  C e p h -R  NG cases, p u b lic  
h e a lth  a u th o r i t ie s  s h o u ld  a lso  c o n t in u e  to  sca le  u p  g e n e ra l g o n o r rh e a  p re v e n t io n  a n d  c o n tr o l  
a c t iv i t ie s .  T h e se  a c t iv i t ie s  a re  d e s ig n e d  to  re d u c e  th e  o v e ra ll g o n o r rh e a  d ise a se  b u rd e n  
th r o u g h  p re v e n t io n ,  e a r ly  d ia g n o s is , t im e ly  a n d  e f fe c t iv e  t r e a tm e n t ,  a n d  p a r tn e r  se rv ice s . 
E ffe c t iv e  g o n o r rh e a  p re v e n t io n  a n d  c o n tr o l  a c t iv i t ie s  w il l  re d u c e  o v e ra ll d ise a se  b u rd e n  a n d  
th u s  th e  re s p o n s e  n e e d e d  w h e n  C eph -R  NG s tra in s  a re  id e n t i f ie d .
N e e d  f o r  A l t e r n a t i v e  T r e a t m e n t  O p t i o n s
C u r re n t ly ,  CDC re c o m m e n d s  d u a l th e r a p y  w ith  c e f t r ia x o n e  2 5 0  m g  in t ra m u s c u la r ly  as a s in g le  
d o s e  w ith  e i th e r  a z ith ro m y c in  1 g ra m  o ra l ly  as a s in g le  d o s e  o r  d o x y c y c lin e  1 0 0  m g  o ra l ly  tw ic e  
a d a y  f o r  7 d a ys  f o r  th e  t r e a tm e n t  o f  u n c o m p lic a te d  g o n o r rh e a  [2 , 3 ] . B ased o n  a v a ila b le  d a ta , 
th is  is th e  m o s t e f fe c t iv e  re g im e n  a g a in s t u ro g e n ita l,  re c ta l,  a n d  p h a ry n g e a l g o n o r rh e a ; 
h o w e v e r ,  i t  is n o t  k n o w n  w h e th e r  use o f  th is  d u a l re g im e n  can  d e la y  th e  e m e rg e n c e  o f  C eph-R  
NG.
In th e  p a s t, CDC re c o m m e n d a t io n s  f o r  g o n o r rh e a  t r e a tm e n t  h a ve  b e e n  ba se d  o n  th e  c r i te r ia  o f  
e f f ic a c y  in > 9 5 %  o f  N . g o n o r r h o e a e  in fe c t io n s  in  th e  p o p u la t io n  [2 8 ] . W h e n  re s is ta n c e  
d e v e lo p e d  to  re c o m m e n d e d  t r e a tm e n t  re g im e n s  in  th e  p a s t, th e  p u b lic  h e a lth  re s p o n s e  w a s  to
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s w itc h  to  an  a l te rn a t iv e  c lass o f  a n t im ic ro b ia ls  th a t  w o u ld  e f fe c t iv e ly  t r e a t  > 9 5 %  o f  N .  
g o n o r r h o e a e  s tra in s  in  th e  U n ite d  S ta te s . T h e  c u r r e n t  la ck  o f  w e ll- s tu d ie d  a n d  e f fe c t iv e  th e r a p y  
f o r  C eph -R  NG is a m a jo r  c h a lle n g e  f o r  p u b lic  h e a lth  a u th o r i t ie s  in  re s p o n d in g  to  th e  th r e a t  o f  
e m e rg in g  C eph -R  NG.
E ffe c t iv e  a l te rn a t iv e  a n t im ic ro b ia ls  o r  a n t im ic ro b ia l  c o m b in a t io n s  f o r  th e  t r e a tm e n t  o f  
g o n o r rh e a  a re  n e e d e d  u rg e n t ly ;  th u s , th e  d e v e lo p m e n t  o f  n o v e l a n t im ic ro b ia ls  a n d  c lin ic a l t r ia ls  
to  s tu d y  c o m b in a t io n s  o f  e x is t in g  a n t im ic ro b ia ls  is n e ce ssa ry .
In c o l la b o ra t io n  w ith  in te rn a t io n a l a n d  n a t io n a l p a r tn e rs ,  CDC w il l  d e v e lo p  an  e v id e n c e  base  o f  
th e  e ffe c t iv e n e s s  o f  e x is t in g  a n t im ic ro b ia ls  a n d  d ru g  c o m b in a t io n s  a n d  s u p p o r t  th e  
d e v e lo p m e n t  a n d  e v a lu a t io n  o f  n o v e l a n t im ic ro b ia l  a g e n ts  a n d  d ru g  c o m b in a t io n s  t h a t  a re  
id e a lly  o ra l,  s in g le  d o s e , m e e t th e  9 5 %  e ffe c t iv e n e s s  s ta n d a rd , a n d  a re  n o t  c o s t - p ro h ib it iv e .
CDC w il l  w o r k  w ith  th e  N a t io n a l In s t itu te s  o f  H e a lth  (N IH ) a n d  th e  n e w  N a t io n a l C e n te r  fo r  
A d v a n c in g  T ra n s la t io n a l S c ie n ce s  (NCATS) to  d e v e lo p  a d d it io n a l g o n o r rh e a  t r e a tm e n t  o p t io n s . 
CDC w il l  a lso  w o r k  w ith  p ro fe s s io n a l o rg a n iz a t io n s  c o n c e rn e d  w ith  a n t im ic ro b ia l  re s is ta n c e , 
su ch  as In fe c t io u s  D iseases S o c ie ty  o f  A m e r ic a  (ID S A), th e  A s s o c ia t io n  o f  P u b lic  H e a lth  
L a b o ra to r ie s  (A PH L), a n d  th e  N a t io n a l C o a lit io n  o f  STD D ire c to rs  (N CSD ). L a s tly , CDC w il l  
c o n t in u e  to  w o r k  w ith  W H O , e s p e c ia lly  in th e  im p le m e n ta t io n  o f  th e  G l o b a l  A c t i o n  P la n  [2 9 ] , as 
C e ph -R  NG is a g lo b a l p u b lic  h e a lth  c o n c e rn .
C o n c l u s i o n s
T h is  re s p o n s e  p la n  is p re p a re d  as a p ro -a c t iv e  a t t e m p t  to  m in im iz e  th e  im p a c t o f  C eph -R  NG 
th r o u g h  th e  im p le m e n ta t io n  o f  e f fe c t iv e  c lin ic a l s e rv ic e s  a n d  p u b lic  h e a lth  p re v e n t io n  p ra c t ic e s . 
A s m o re  e v id e n c e  b e c o m e s  a v a ila b le , th e  case  d e f in i t io n s ,  c lin ic a l m a n a g e m e n t,  a n d  p u b lic  
h e a lth  re s p o n s e  s tra te g ie s  o u t l in e d  in th is  d o c u m e n t w i l l  n e e d  to  be  re v ie w e d  a n d  re v is e d . 
B a rr ie rs  to  th e  e f fe c t iv e  c o n tr o l  o f  C eph -R  NG e x is t, a n d  in  an  e ra  o f  d e c l in in g  STI p u b lic  h e a lth  
in f r a s t ru c tu r e ,  lo c a l, s ta te , a n d  fe d e ra l re s o u rc e s  m a y  n e e d  to  be  re p r io r i t iz e d  to  im p le m e n t  
th is  p la n . H o w e v e r , a c o o rd in a te d  a n d  s u s ta in e d  e f f o r t  t h a t  in c lu d e s  c lin ic ia n s , la b o ra to r ia n s , 
a n d  s ta te  a n d  lo ca l h e a lth  d e p a r tm e n ts  w il l  l im i t  th e  im p a c t  o f  a n t im ic ro b ia l- r e s is ta n t  N .  
g o n o r r h o e a e .  P re p a ra t io n  a n d  a c t io n  n o w , p r io r  to  th e  e m e rg e n c e  o f  re s is ta n t s tra in s , w il l  
a l lo w  f o r  a m o re  e f fe c t iv e  a n d  less c o s t ly  re s p o n s e  la te r .
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A p p e n d i x  I: 
C o n t a c t  I n f o r m a t i o n  a n d  S e l e c t e d  W e b  R e s o u r c e s
T o  r e p o r t  ca se s  o f  s u s p e c t o r  p ro b a b le  C e p h -R  NG  to  CDC:
Email g is p in fo @ c d c .g o v  o r  ca ll (4 0 4 ) 6 3 9 -8 6 5 9
T o  c o n s u lt  w i t h  a S T D /H IV  P re v e n t io n  T ra in in g  C e n te r :
V is it  w w w .n n p tc .o rg  f o r  th e  c o n ta c t  in fo rm a t io n  o f  th e  T ra in in g  C e n te r  c lo s e s t to  y o u
In s t r u c t io n s  f o r  s h ip p in g  is o la te s  t o  CDC c a n  b e  fo u n d  a t :
w w w .c d c .g o v /s td /G o n o r rh e a /a rg /s p e c im e n _ s h ip p in g _ in s t ru c t io n s 1 -2 9 -0 8 .p d f
E le c t ro n ic  c o p ie s  o f  th e  I n t e r v i e w  R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a  a n d  in s t r u c t io n s  ca n  b e  
fo u n d  a t :
h t tp : / /w w w .c d c .g o v /s td /P ro g ra m /fo r m s /G C _ C T _ I  R _ 6 _ 0 5 _ 2 0 0 8 .p d f 
h t tp : / /w w w .c d c .g o v /s td /P ro g ra m /fo rm s /G C -C T /G C _ C T - IR In s tru c t io n s .p d f
STD T r e a tm e n t  G u id e l in e s :
h t tp : / /w w w .c d c .g o v /S T D / t r e a tm e n t /
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A p p e n d i x  II :  
S a m p l e  R e g u l a t o r y  L a n g u a g e  f o r  M a n d a t e d  R e p o r t i n g  o f  
A n t i m i c r o b i a l  S u s c e p t i b i l i t y  T e s t i n g  ( A S T )  R e s u l t s
T h e  fo l lo w in g  is an  e x c e rp t f r o m  N e w  Y o rk  C ity 's  re g u la t io n s  c o n c e rn in g  re p o r ta b le  c o n d it io n s :
"T h e  d i r e c to r  o f  a c lin ic a l la b o ra to r y  c o n d u c t in g  an  e x a m in a t io n  o f  a s p e c im e n  s u b m it te d  f o r  
a n a ly s is  s h a ll, e x c e p t as n o te d  b e lo w  w ith  re s p e c t to  b lo o d  b a n ks , re p o r t  to  th e  D e p a r tm e n t ,  
w ith in  2 4  h o u rs  o f  o b ta in in g  re s u lts , a ll p o s it iv e  o r  re a c t iv e  la b o ra to r y  f in d in g s  w h ic h  in d ic a te  
th e  p re s u m p t iv e  o r  c o n f irm e d  p re s e n c e  o f  a n y  d ise a se  o r  c o n d it io n  re q u ire d  to  be  re p o r te d  b y  
s u b d iv is io n  (a) o f  § 1 1 .0 3  o f  th is  C o d e , a n d  a lso  a n y  la b o ra to r y  f in d in g s  w h ic h  a re  o th e rw is e  
re q u ire d  to  be  re p o r te d  p u rs u a n t to  th is  A r t ic le ;  ... R e p o rts  s h a ll c o n ta in  a ll o f  th e  in fo rm a t io n  
a n d  d a ta  e le m e n ts  re q u ire d  b y  th e  re p o r t in g  fo rm s  o r  e le c tro n ic  re p o r t in g  fo r m a t  a p p ro v e d  b y  
th e  D e p a r tm e n t ,  in c lu d in g  b u t  n o t  l im ite d  to :  ... (8 ) T h e  a n t ib io t ic  s u s c e p t ib i l i ty  te s t in g  re s u lts  
f o r  b a c te r ia l d ise a se s  lis te d  u n d e r  s u b d iv is io n  (a) o f  § 1 1 .0 3  o f  th is  C o d e . T h is  re q u ire m e n t  
in c lu d e s  t r a d i t io n a l  b ro th ,  a g a r a n d  n e w e r  a u to m a te d  m e th o d s  o f  a n t ib io t ic  s u s c e p t ib i l i ty  
te s t in g ,  as w e ll as m o le c u la r -b a s e d  m e th o d s  th a t  a ssay  f o r  m o le c u la r  d e te r m in a n ts  o f  a n t ib io t ic  
re s is ta n c e ."
R e fe re n c e : N e w  Y o rk  C ity , N .Y ., T it .  2 4 , H e a lth  C o d e , § 1 3 .0 3 .
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A p p e n d i x  I I I :  
T a b l e :  C L S I  c e f i x i m e  a n d  c e f t r i a x o n e  a g a r  d i l u t i o n  M I C  a n d  
d i s k  d i f f u s i o n  z o n e  d i a m e t e r  s t a n d a r d s  f o r  N . g o n o r r h o e a e  
[ 2 6 ]
A n t im ic ro b ia l  a g e n t M IC  b y  a g a r d i lu t io n Z o n e  d ia m e te r  b y  d is k  d if fu s io n
C e fix im e > 0 .2 5  n g /m l < 3 1  m m
> 0 .5  n g /m l N o t d e f in e d
C e ftr ia x o n e > 0 .1 2 5  n g /m l N o t d e f in e d
> 0 .2 5  n g /m l < 3 5  m m
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A p p e n d i x  IV :
I n t e r v i e w  R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a  
a n d
I n s t r u c t i o n s  f o r  I n t e r v i e w  R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a
25
P atien t ID
I n t e r v i e w  R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a
Condition(s) R e in fec tion?  If yes, # Case ID
Y N U
Y N U
In te rv iew  
Record ID
Name D em ograph ics
_L L Y N U R
Age Hispanic/Latino
Middle Name
AI/AN A B NH/PI W U R
Preferred Name / AKA Maiden Name Sex at Birth S M Sep D W C U
Marital Status
A ddress Phone/C ontact























Provider Test Specimen Source Qualitative Result
_  n  0 0 Q0
R R R R  
R R R R
Pregnant at Exam?
Y N U R





Treatm ent C om m ents :
P rov ider Drug and Dosage
P rov ide r C ho ice :
R isk Factors Y - Yes N - No R - Refused to Answer D - Did not Ask
In the  last 12 m on ths  has the patient:
1. Had sex with a male?
2. Had sex with a female?
3. Had sex with an anonymous partner?
4. Been incarcerated?





5. During the past 12 months, which of the 
following injection or non-injection drugs have 
been used?




□  Erectile dysfunction 
medications (e.g., Viagra)
□  o ther
Other, specify:
R eporting
In fo rm ation
C ondition 1
Method o f Case 
Detection





Date First Assigned for ,
Interview L
Worker ___






In fo rm a tion
C ondition 2
Method o f Case 
Detection
Date First Assigned for
Interview L






Date Original Interview L
Supervisor #
_L_____ L
Worker Date Case Closed
Loca l Use: A B C D E F G H I J K L
2 2
Date of Birth
M I F Race
R
M Y M M II Y
Y N R D





















Page 2 Case ID
H IV  T es tin g
Tested fo r  HIV at th is  event?  
Date Collected
 /  / -------------------------------
Y 11 N 11 u 11 R 1| Not Asked
Provider Test Specimen
Source




S igns and S ym ptom s STD H is to ry In te rv iew  Period Partners




Previous STD History? Y 11 N I 1 u I 1 R
L L
Condition Dx Date (mmLyyyy) Rx Date (mmLyyyy)
L L
1. L L
















Exposure L_____ L_ 0 E 0 0 0 Y N U R
Y N U R
Condition
































Exposure 0 0 0 0 0 Y N U R Y ” 1 U 1»
Condition





2 _L_____ L_ _L_____ L_
Ix Type Dispo
Dispo Date
S ocia l H is to ry In terview , In ternet, and Investiga tion  C om m ents













Did not ask 
Refused to answer
Did not ask 
Refused to answer












1 II 2 3
DIS #Ix DIS #Ix Date
FR#
1 II 2 3
x Date Ix DIS # DIS #
First Name
FR#
1 II 2 3
DIS #x DIS #x Date
FR#
1 II 2 3
x DIS # DIS #
First Name
FR#
1 II 2 3
DIS #x DIS #x Date
1 II 2 3
x Date x DIS # DIS #
L
P atien t ID
I n t e r v i e w  R e c o r d  f o r  G o n o r r h e a / C h l a m y d i a
Condition(s) R e in fec tion?  If yes, # Case ID
* 1
N U
N U < 3 >
In te rv iew  
Record ID
Name Dem ograph ics
_L L_
Middle Name
Y N U R
Hispanic/Latino
A B NH/PI W U R
Preferred Name / AKA Maiden Name Sex at Birth S M Sep D W C U
Marital Status
A ddress Phone/C ontact
Ü Ï























Test Specimen Source Qualitative Result
_ n  0 0 0 0
Pregnant at Exam?
R R R R
R R R R
Y N U R
[ @ ]  
# Weeks
0 0 0 E





Treatm ent C om m ents: _
P rov ider Drug and Dosage
P rov ide r Choice:.
ISRisk Facto rs Y -Y e s ,  A n a l o r V a g in a l I n te r c o u r s e  (w ith  o r w i th o u t  O ra l S e x ) O -Y e s ,  O ra l S e x  O n ly  U -U n s p e c if ie d  T y p e  o f S e x  N -N o  R -R e fu s e d  to  A n s w e r  D -D id  N o t A s k Y - Yes N - No R - Refused to Answer D - Did not Ask
In the  last 12 m on ths  has the  patient:
1. Had sex with a male? Y O U N R D 1
2. Had sex with a female? Y O U N R D 1
3. Had sex with an anonymous partner? Y O U N R D 1
4. Been incarcerated? Y N R D 1
Crack Methamphetamines
0 0 0 0  m r N 0 0
1— 11— 11— 11— 1 L _ J L ^ L _ I I _ I  Erectile dysfunction 
Cocaine Nitrates/Poppers medications (e g 
0 0 0 0  0 0 0 0  Viagra)
Heroin
5. During the past 12 months, which of the 
following injection or non-injection drugs have 
been used?
None
0 0 1 0 0
0 0 1 0 1 0  0 0 1 0 0
Other 0 0 1 0 1 0
Other, specify:
R eporting
In fo rm a tion
C ondition 1
R eporting
In fo rm a tion
C ondition 2
Method o f Case 
Detection
Date First Assigned for 
Interview -
F ac ility  F irs t Tested
If Other, Describe

















Date First Assigned for 
Interview
Worker







Loca l Use: A B C D I S G H K
2 2
Date of Birth
M I F Race
R
M Y M M II Y


















Page 2 Case ID
HIV T es tin g
Tested fo r HIV at th is  event?
Date Collected
 /  / -------------------------------
Y 11 N 11 u 11 R 1| Not Asked
Provider © Test SpecimenSource




S igns and Sym ptom s STD H is to ry In te rv iew  Period Partners





Y 11 N I 1 u I 1 R
_L L
_L L
If  Other, Please Describe:
Previous STD History?

















Exposure L_____ L_ 0 E 0 0 3 Y N U R Y N U R
Condition































Exposure H 0 0 0 0 Y N U R Y ” 1 U R
Condition





2 _L_____ L_ _L_____ L_
Ix Type Dispo
Dispo Date
S ocia l H is to ry













Did not ask 
Refused to answer
Did not ask 
Refused to answer
In terview , In ternet, and Investiga tion  C om m ents [ 22












1 II 2 3
DIS #Ix DIS #Ix Date
FR#
1 II 2 3
x Date Ix DIS # DIS #
First Name
FR#
1 II 2 3
DIS #x DIS #x Date
FR#
1 II 2 3
x DIS # DIS #
First Name
FR#
1 II 2 3
DIS #x DIS #x Date
1 II 2 3
x Date x DIS # DIS #
L
1
The Centers for Disease Control and Prevention (CDC) Interview Record is primarily designed for use by state and local 
Disease Intervention Specialists (DIS) who interview individuals with sexually transmitted diseases (STDs), including 
HIV/AIDS and other related conditions, and conduct sex and needle sharing partner notifications and referrals. This 
instrument is meant to assist DIS and their managers in documenting and evaluating case management activities 
according to local program priorities and/or regulations. State and local program priorities and regulations will also 
determine what types of information should be documented and retained on this form. A small portion of the information 
recorded within this document will be transmitted to CDC.
Interview Record Instructions (GC/CT Version)
Though some data elements (excluding personal identifiers, i.e. names, addresses, telephone numbers, etc.) will be 
forwarded to CDC, this form does not represent a document that is to be used for federal data collection purposes in its 
entirety. Also, this form and accompanying documentation is an example of an Interview Record that can be used by 
local and state programs and is made available for local and state program use and adaptation.
These instructions describe how to complete the interview record form. Each numbered item in the instructions 
corresponds to a number on the sample interview record form.




Patient ID Number: Document the patient ID for this person, if known or applicable.
NOTE: If using a computerized system, this number may be assigned by the software system.
Condition: Document the specific disease code for the diagnosed and/or interviewed condition. Conditions will be 
interviewed for and/or documented on an interview form depending on local programmatic procedures and policies in 
place. If one of the conditions being interviewed is syphilis or HIV related, this is not the proper interview record to be 
completed.
030 - HepB acute w/o delta 100 - Chancroid
031 - HepB acute w / delta 200 - Chlamydia
033 - HepB chronic w/o delta 300 - Gonorrhea (uncomplicated)
034 - HepB chronic w / delta 350 - Resistant Gonorrhea
042 - Hepatitis delta 400 - Non-Gonoccocal Urethritis (NGU)
051 - Hepatitis C, acute 450 - Mucopurulent Cervicitis (MPC)
053 - Hepatitis E 490 - PID Syndrome
054 - Hepatitis C, chronic 500 - Granuloma Inguinale
070 - Hepatitis, unknown 600 - Lymphogranuloma Venereum (LGV)
Second Condition: Document a 2nd Condition, if one exists, using same list as above for disease(s) interviewed.
Reinfection? If yes, #: Document if the interviewed condition is a ReInfection of same condition within the last 12 
months. If yes, document the number of times, including current infection, patient has been infected with this conditition 




Case ID(s) Number: Document the case ID number(s) for the corresponding condition(s). 
NOTE: If using a computerized system, this number may be assigned by the software system.
Interview Record ID: Document the interview record number for this case, if known. This number is used for data 
processing/control purposes to link related cases.
NOTE: If using a computerized system, this number may be assigned by the software system.
Name





Date of Birth: Document the patient's date of birth. Leave blank if unknown.
Age: Document the patient's age at the time of initial exam for the earliest condition reported on this interview record. 
Document '0' if age is less than one year or '999' if unknown.
Hispanic or Latino*: Place an “X ” in the appropriate box to identify the ethnic group with which the p a tie n t  self identifies. 
Hispanic origin means a person of Spanish, Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish 
culture or origin, regardless of race.
Y - Yes, Hispanic/Latino 
N - No, not Hispanic/Latino 
U - Unknown 
R - Refused to answer
Sex at Birth: Place an “X ” in the appropriate box for the patient's biologic sex a t birth: male or female. Leave blank if 
unknown.
Race*: Place an “X ” in as many boxes as applicable. Base on the racial group(s) with which the p a tie n t  self identifies.
AI/AN (American Indian or Alaska Native): A person having origins in any of the original peoples of North 
and South America (including Central America).
A (Asian): A person having origins in any of the original peoples of the Far East, Southeast Asia, or the 
Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the 
Philippine Islands, Thailand, and Vietnam.
B (Black or African American): A person having origins in any of the black racial groups of Africa.
NH/PI (Native Hawaiian or Other Pacific Islander): A person having origins in any of the original peoples 
of Hawaii, Guam, Samoa, or other Pacific Islands.
W (White): A person having origins in any of the original peoples of Europe, the Middle East, or North 
Africa.
U (Unknown): The patient could not answer this question for any reason.
R (Refused): The patient refused to answer this question.
Marital Status: Place an “X ” in the appropriate box indicating marital status at the time of the interview or morbidity 
report.
S - Single, Never Married W - Widowed
M - Married C - Cohabitation
SEP - Separated U - Unknown
D - Divorced R - Refused to Answer
©
Address
Address: Document the complete address where the patient currently resides. If th e  p a tie n t is  cu rren tly  in stitu tio n a lized  
(e .g ., in jail, in a  g ro u p  h o m e , in a  m e n ta l  h e a lth  facility, e tc .) , d o  n o t d o c u m e n t  th e  a d d r e s s  o f  th e  in stitu tion  u n le s s  it is  
d e te r m in e d  th a t th e  co nd ition  w a s  a c q u ire d  in th e  in stitu tion . Include apartment number, city, county, 2-letter abbreviation 
for the state, 5-digit zip code, district or region (if applicable), and country for the address where the patient resides.
Note: Work address(es) can be documented within the
NOTE: If this is a temporary address, record the patient's permanent address and any other interview period addresses in 
the Comments section. For an institutionalized person, list the last known address where the person resided.
NOTE: Work address(es) can be documented within the comment section.
Living With: Document the RELATIONSHIP (such as spouse, parents, sibling, roommate, etc., n o t  th e  n a m e )  of those 
living with the patient.
Residence Type: Document the appropriate code in the box for the type of residence for the above address.
A - Apartment N - Homeless
B - Mobile Home O - Other
3
Address
C - Migrant Camp P - Prison
D - Dorm Q - Mental Health Center
G - Group Home R - Rehabilitation Center
H - House/Condo U - Unknown
J - Jail X  - Drug Treatment/Detox Center
M - Hotel/Motel Y - Juvenile Detention
Time At Address: Document the length of time the patient has lived at the current address, in this state/territory, and in
the country. Also, place an “X ” in the appropriate box to indicate whether the time at the corresponding location is in (W )
weeks, (M) months, or (Y ) years. If length of time is unknown, please document “UNK”.
Currently Institutionalized?: Place an “X ” in the appropriate box to indicate if the patient is  institutionalized (i.e., in jail, in
a group home, in a mental health facility, etc.). If institutionalized, document the n a m e  of the facility.
Institution Type: Document the appropriate code in the box for the type of facility where the patient is currently
institutionalized.
G - Group Home Q - Mental Health Center
J -  Jail R - Rehabilitation Center
O - Other X - Drug Treatment/Detox Center




Phone/Contact: Document the phone number(s) where the patient can be reached and the patient's e-mail address(es) if 
applicable. Include an emergency contact name, phone number, and relationship to patient, if available.
STD Testing
Test Results: Summarize all STD lab results relevant to this case, noting at least the last negative result, the first positive 
result, and the most recent test if applicable.
NOTE: HIV testing is not to be documented here but in HIV Testing Section.
NOTE: Hepatitis testing can be documented within this section.
Date Collected - Document the date the specimen was obtained from the patient.
Provider - Document the specific name or code of the provider (physician, clinic, hospital, etc.) who ordered the testing.
Test - Document the name (or type) of the test performed (e.g., RPR, TP-PA, darkfield, etc.). Ensure that the test type and 
condition (disease) being asked for is clear.
Source - Document the code from the list below for the source of specimen collection.
01 - Cervix/Endocervix 09 - Rectum
02 - Lesion-Genital 10 - Urethra
03 - Lesion-Extra Genital 11 - Urine
04 - Lymph Node Aspirate 12 - Vagina
05 - Oropharynx 13 - Blood/Serum
06 - Ophthalmia/Conjunctiva 14 - Cerebrospinal fluid (CSF)
07 - Other 88 - Not Applicable
08 - Other Aspirate 99 - Unknown
Qualitative Results -  Place an “X ” in the appropriate box to indicate the test result(s).
P - Positive 
N - Negative
4
I - Indeterminate/Equivocal 
U - Unknown/No Result
Pregnancy
Pregnant at Exam?*: Place an “X ” in the appropriate box to indicate the patient's pregnancy status at initial exam for the 
condition(s) documented on this interview record. If the patient was pregnant at the time of the initial exam, document the 
duration of the pregnancy in weeks at exam. Y - Yes, N - No, U - Unknown, R - Refused to Answer.
Pregnant in Last 12 Months?: Determine if the patient has been pregnant during the last 12 months and place an “X ” in 
the appropriate box. If currently pregnant, a “Yes” answer indicates that the patient had a n o th e r  pregnancy within the past 
12 months, not including her current pregnancy. Y - Yes, N - No, U - Unknown, R - Refused to Answer.
STD T reatment
Treatment: Document all relevant treatment regimen(s). For the recommendations of adequate treatment, see the 
current CDC T reatment Guidelines.
Treatment Date - Document the date treatment was first started.
Provider - Document the name or code of the provider (physician, clinic, hospital, etc.) that provided the treatment.
Drug and Dosage - Document the name of the drug given, as well as the dosage and duration (e.g., 2.4 Bicillin x 3 weeks 
or Doxycycline 100mg bid x 28 days).
Treatment Comments - Place treatment related comments, if any, here.
Provider Choice - Document patient's preferred provider for treatment.
Risk Factors
NOTE: Each risk factor should be addressed for the last 12 months prior to the date of the original interview. Also, for the 
purposes of risk assessment, sex is defined as having engaged in oral, anal and/or vaginal contact with another individual.
NOTE: For each risk 1 -  3, the patient should be asked what type of sexual exposure occurred. Document the 
appropriate response, one response per risk factor.
Y -  Yes, Anal or Vaginal Intercourse (with or without Oral Sex)
O -  Yes, Oral Sex Only 
U -  Unspecified Type of Intercourse 
N -  No Sexual Exposure 
R -  Refused to Answer 
D -  Did Not Ask
Anonymous - a sex partner whose name is unknown (e.g., met at a sex party, website, bathhouse, etc.).
Drug Use Behaviors: Document the appropriate response of Y - Yes, N - No, R - Refused to Answer, or D - Did Not Ask. 
Please place an “X ” in the appropriate box(es) for all recreational drug types used within the last 12 months.
Condition(s) Reporting Information
Method of Case Detection: Document the specific method of case detection code, i.e., how the patient first came to the 
attention of the health department, for each condition(s).
20 - Screening: An asymptomatic patient was identified through screening (routine testing of populations 
who are asymptomatic in order to identify those with disease). Examples of screening programs include 
health department outreach to high-risk populations (e.g., commercial sex-workers), h Iv  care clinics, family 
____________ planning, blood donation, corrections-based, and prenatal. This includes STD and other health department
5
clinic visits by a client who tests positive for a condition with which they were unaware (e.g., asymptomatic 
walk-ins) of before being seen at the clinic.
21 - Self-Referred: Refers to patient who sought health services because of signs of an STD and were 
subsequently tested for the disease being reported. This includes symptomatic STD clinic testing.
22 - Patient Referred Partner: Patient referred by another infected person. This may be a named or 
unnamed partner. No health department involvement was necessary for this referral.
23 - Health Department Referred Partner: This patient is a named partner of a known case. Patient 
identified through DIS, or other health department personnel, activity following an interview of another 
known case. The health department was involved in the referral of this individual (e.g., the DIS contacted, 
called, visited, sent letter, etc., the patient to inform them of their need to be tested).
24 - Cluster Related: Patient was originally identified as a Social Contact (Suspect) or Associate. Cluster 
brought to the attention of the program as a result of a DIS interview.
88 - Other: In the event of NONE of the above being applicable, accurately describe how the patient came 
to the attention of the health department.
Interview Period: Document the interview period in months for each condition.
Type Facility First Tested: Document the specific ty p e  o f  facility  code where the patient was first tested for each 
condition. If '88' (Other) please describe as specifically as possible in the space provided.
01 - HIV Counseling/Testing Site 13 - Blood Bank
02 - STD Clinic 14 - Labor and Delivery
03 - Drug Treatment 15 - Prenatal
04 - Family Planning 16 - Job Corps
05 - RETIRED 17 - School-based Clinic
06 - TB Clinic 18 - Mental Health Services
07 - Other HD Clinic 29 -  Hospital (Other)
08 - Private MD/HMO 66 - Indian Health Services
09 - RETIRED 77 - Military
10 - Hospital (ER) 88 - Other
11 - Correctional facility 99 - Unknown
12 - Lab
Date of Laboratory Report: Document the date the first laboratory report related to the interviewed condition 
documented on this interview record was initially received at the health department (or any authorized public health 
agency, e.g., the STD clinic) for each condition(s).
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NOTE: Relevant HIV testing and interview may occur on the same day. Also, the answer “No” for Tested for HIV at this 
event includes opt-out/routine HIV testing in settings where HIV pretest counseling is not conducted.
Previously Tested for HIV?: Place an “X ” in the appropriate box to indicate whether the patient has tested for HIV prior to 
the event that led to the Original Interview. Y - Yes, N - No, U -  Unknown, R - Refused to Answer, or Not Asked.
HIV Test Results: Place the most recent or relevant HIV lab results. Document the date collected, the provider name or 
code who ordered the test, the name of the test, the source, and the qualitative result (see item #9 for codes).
Provider Confirmed -  Place a 'Y' for 'Yes' if HIV test result(s) has been provider confirmed by record search or direct 
contact with a provider. Place an 'N' for 'No' if based on interviewee responses only.
Signs and Symptoms
Signs and Symptoms: Determine if there are signs or symptoms related to the condition(s) documented on this interview 
record. This includes all symptoms experienced by the patient and signs observed by a clinician. Additional signs and 
symptoms can be documented within the Interview/Investigation Comments.
Signs/Symptoms - Document the code for each sign/symptom observed on exam or described:
A - Discharge or Mucopurulent Cervicitis (MPC) L - Swelling/Inflammation
B - Chancre, Sores, Lesions, or Ulcers M - Mucous Patch
C - Rash N - Lymphadenopathy
D - Dysuria O - Other
E - Itching P - Balanitis
F - Alopecia (Hair loss) Q - Fever
G - Condyloma Lata R - Cervical Friability
H - Bleeding S - Ectopy
I - Pharyngitis (Sore Throat) T - Epididymitis
J - Painful Sex V - Proctitis
K - Abdominal Pain W  - Adnexal tenderness/Cervical motion tenderness
Earliest Observation Date - Document the earliest date the symptom was first experienced by the patient and/or the date 
the sign was first observed by a clinician.
Anatomic Site* - Document the code indicating the anatomic site of the sign/symptom.
A - Anus/Rectum H - Eye-Conjunctiva
B - Penis I - Head
C - Scrotum J - Torso
D - Vagina K - Extremities (Arms, Legs, Feet, Hands)
E - Cervix N - Not Applicable
F - Naso-Pharynx O - Other
G - Mouth/Oral Cavity U - Unknown
Duration (Days) - Document the number of days signs/symptoms were present. Document “99” if unknown.
If Other, Please Describe - if sign/symptom code “O” is used, please describe in the space provided.
STD History
STD History*: Place an “X ” in the appropriate box indicating if the patient has a history of STDs (prior to the condition(s) 
documented on this interview record). HIV testing history should be documented in the HIV Testing section.
Y - Yes, patient has a history of STD 
N - No, patient has never had a prior STD 
U - Unknown if patient has had a prior STD
R - Patient refused to answer any questions regarding prior STD History
If 'Yes', document the condition code(s), diagnosis date(s) (MM/YYYY), and treatment date(s) (MM/YYYY) in the space 
provided.
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030 - HepB acute w/o delta 100 - Chancroid
031 - HepB acute w / delta 200 - Chlamydia
033 - HepB chronic w/o delta 300 - Gonorrhea (uncomplicated)
034 - HepB chronic w / delta 350 - Resistant Gonorrhea
042 - Hepatitis delta 400 - Non-Gonoccocal Urethritis (NGU)
051 - Hepatitis C, acute 450 - Mucopurulent Cervicitis (MPC)
053 - Hepatitis E 490 - PID Syndrome
054 - Hepatitis C, chronic 500 - Granuloma Inguinale
070 - Hepatitis, unknown 600 - Lymphogranuloma Venereum (LGV)
Interview Period Partners
Interview Period Partners: Document the total number of female, male, and transgender sex partners claimed by this 
patient during the interview period for each Condition(s). Note that this includes initiated partners, marginal partners, and 
anonymous partners. For example, the patient may claim 10 sex partners during the 3-month interview period (Primary 
Syphilis), while there is only enough information to initiate 3; the total of 10 (rather than 3) should be documented for 
interview period partners. Select 'unknown' if patient is unsure or 'refused' if the patient would not answer the question. 
Document “0” if there are no partners for corresponding gender field.
Partner/Cluster Information
This section of the form is used to record all interview activity and the results of investigations regarding partners and 
clusters. Guidelines for completing the partner/cluster initiation section are:
NOTE: If a patient is interviewed, complete at least one partner/cluster section. If no partners/clusters are added, 
document the date of interview, the number of the DIS/worker who conducted the interview, and the type of interview 
conducted.
NOTE: Document only the names of sex partners, social contacts and associates fo r  w hom  su ffic ie n t in fo rm ation  has 
been obta ined to  in itia te  a Field Record. Information on marginal contacts and clusters should be documented in the 
space provided and/or on a buff.
NOTE: All re-interview or cluster activity must be listed in separate sections. Use of Re-Interview and Cluster Interview 
Forms are encouraged for complete documentation.
NOTE: Clusters must be n a m e d  b y  th e  in d e x  p a tien t, n a m e d  c o n ta c ts  o r  n a m e d  c lu s te r s  to be documented on the 
interview record. General field screening not specifically associated with this interviewed patient should not be included in 
this section. Other mechanisms must be used to collect this type of screening information.
Name: Document the Last and First name and, if applicable, known aliases of the partner/cluster.
Ju risd ic tio n : Document the county, state or country code or name for where the partner/cluster resides. Use of code or 
name depends on local programmatic discretion.
P/Cl (Partner/C luster): Document the appropriate identifier for the specific type of partner or cluster (Suspect and/or 
Associate).
P A R T N E R  - Persons having sexual activities (of any type) or sharing needles with the Index patient.
P1 - Sex Partner
P2 - Needle sharing Partner
P3 - Both Sex and Needle sharing Partner
S O C IA L  C O N T A C T  (S U S P E C T )  - Persons named by an infected person (e.g., the Index patient or an infected 
partner or cluster).
51 - Person who has or had symptoms suggestive of the Condition(s) documented.
52 - Person who is named as a sex partner of a known infected person.
53 - Any other person who would benefit from an exam (i.e., someone who has engaged in a behavior that
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P artner/C luster Inform ation
might put them at risk).
A S S O C IA T E  - Persons named by an uninfected partner or cluster.
A1 - Person who has or had symptoms suggestive of the Condition(s) documented.
A2 -Person who is named as a sex partner of a known infected person.
A3 - Any other person who would benefit from an exam (i.e., someone who has engaged in a behavior that 
might put them at risk).
Exposure to  O rig ina l Patient: Document the Index Patient's contact with the partner.
First E x p o s u re  - Document the date of the first sexual/needle-sharing exposure to the Index patient.
Freq. (F re q u en c y )  - Document the frequency (number) of sexual/needle-sharing exposure to the Index patient between the 
first and last (most recent) exposure. This should be described as specifically as possible: 1x = one time, 2x/wk = two 
times a week, etc. If the frequency is unknown, document “99”.
L a s t E x p o s u re  - Document the date of the last (most recent) sexual/needle-sharing exposure.
NOTE: Exposure information should only be documented for partners of the Index patient; only what the Index patient 
claimed as exposure should be documented, NOT what the partners claimed as exposure.
Sex: Place an “X ” in the appropriate box to indicate the gender of the partner or cluster, as identified by the person being 
interviewed: M - Male, F - Female, T - Transgender, U - Unknown, R - Refused.
N O T E : If tra n sg e n d e r  is  m a rke d , M TF  or F T M  sh o u ld  b e  d o c u m e n te d  o n  th e  c o rre sp o n d in g  C lu s te r  In te rv iew  R eco rd .
Pregnant: Document if this partner/cluster is pregnant: Y - Yes, N - No, U - Unknown, R - Refused to Answer.
Spouse: Document if this partner/cluster is the Index patient's spouse: Y - Yes, N - No, U - Unknown, R - Refused to 
Answer.
IX Date (Interview  Date): Document the date the original interview, re-interview or cluster interview was performed. 
Document interview dates where no partners or clusters are initiated as well using.
Init. Date (In itia tion  Date): Document the date this partner/cluster was initiated for field investigation.
IX DIS # (Interview  DIS): Document the worker number of the DIS who conducted the interview for each condition (if 
multiple conditions). Also, document the worker number if no contacts or clusters are initiated.
Ix Type (In terview  Type): Document the type of interview that was the source of the partner/cluster information.
0  - Original In te rv iew  - the initial interview with an infected patient.
R - R e -In te rv ie w  - any interview after the Original Interview of an infected patient.
C - C lu s te r  In terv iew  -  any interview of a partner or cluster regarding the index case.
U - U n a b le  to in te rv ie w  - (may include situations where the Index patient was not interviewed, but sex 
partners and/or clusters were initiated from other activities).
Referral: This describes how initiated partners and clusters are brought to examination and/or treatment. This 
documentation will take place at the time of the disposition (closure) of the field record. Document the type of referral for 
each condition.
1 - Provider: DIS or other health department staff were involved in the referral of this partner/cluster.
2 - Patient (Client): No health department involvement in the referral of this partner/cluster.
3 - Dual (Contract): A combination of provider and patient effort to bring contact/cluster to services.
FR # (Field Record Number): Document the entire field record number(s) for the partner/cluster initiated. This number is 
located in the lower left corner of the CDC form 73.2936S, or may be generated by the software system.
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Dispo (Disposition): Document the STD or HIV disposition 
STD Dispositions 
A - Preventative Treatment 
B - Refused Preventative Treatment 
C - Infected, Brought to T reatment 
D - Infected, Not Treated 
E - Previously Treated for This Infection 
F - Not Infected
G - Insufficient Information to Begin Investigation 
H - Unable to Locate
J - Located, Refused Examination and/or Treatment 
K - Out Of Jurisdiction 
L - Other
code from the field record for each Condition(s):
HIV D ispos itions
1 - Previous Positive
2 - Previous Negative, New Positive
3 - Previous Negative, Still Negative
4 - Previous Negative, Not Re-tested
5 - Not Previously Tested, New Positive
6 - Not Previously Tested, New Negative
7 - Not Previously Tested, Not Tested Now
G - Insufficient Information to Begin Investigation 
H - Unable to Locate
J - Located, Refused Counseling and/or Testing 
K - Out Of Jurisdiction 
L - Other
Dispo Date (Disposition Date): Document the appropriate date as it relates to the following examination or treatment 
situation for each Condition(s).
N e w ly  E x a m in e d  a n d  T re a te d  - Use the date of treatment.
N e w ly  E xa m in e d , n o t  T re a te d  - Use the date of examination.
P re v io u s ly  E x a m in e d  a n d /o r  T re a te d  - Use the date the partner/cluster investigation is closed (i.e., the date 
the investigator became aware of the previous examination and/or treatment).
N o t E x a m in e d  - Use the date the investigation is closed.
NOTE: A partner/cluster C A N  N O T  be dispositioned b e fo r e  it is initiated. Therefore, if examination and/or treatment
occurred prior to the partner/cluster being initiated (e.g., disposition 'E' or 'A'), the disposition date can be no earlier than
the initiation date.
Cond. (Condition): If partner/cluster is dispositioned as infected, whether previously or currently, document the diagnosis 
code for the condition.
030 - HepB acute w/o delta 450 - Mucopurulent Cervicitis (MPC)
031 - HepB acute w / delta 490 - PID Syndrome
033 - HepB chronic w/o delta 500 - Granuloma Inguinale
034 - HepB chronic w / delta 600 - Lymphogranuloma Venereum (LGV)
042 - Hepatitis delta 710 - Syphilis, primary
051 - Hepatitis C, acute 720 - Syphilis, secondary
053 - Hepatitis E 730 - Syphilis, early latent
054 - Hepatitis C, chronic 740 - Syphilis, unknown duration
070 - Hepatitis, unknown 745 - Syphilis, late latent
100 - Chancroid 750 - Syphilis, late w/ symptoms
200 - Chlamydia 800 - Genital Warts
300 - Gonorrhea (uncomplicated) 850 - Herpes
350 - Resistant Gonorrhea 900 - HIV Infection
400 - Non-Gonoccocal Urethritis (NGU) 950 - AIDS (Syndrome)
DIS #: Document the worker number of the DIS who brought this partner or cluster to d i s p o s i t io n  for each Condition(s).
@
Social History
Places Met Partners: Document the codes for the types of places where the patient m e t  sex partners within the last 12 
months (document as many as apply):
A - Adult Book Store/Cinema J - Jail/Prison S - Partner's Home
B - Bars K - Clubs T - Street
C - Cruising in Automobile L - Beach U - Circuit Party
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D - Dance Halls M - Motel/Hotel V - Cruise (Boat)
E - Escort Services N - Shopping Mall W  - Work
F - Baths/Spas/Resorts O - Other X - Park/Rest Area
G - Place of Worship P - Project/Shelter
H - Home Q - School
I - Chat Rooms/Lines/Email/Internet R - Gyms/Health Clubs
Document the names (or descriptions) of places the patient goes to m e e t  sex partners. Document 'did not ask' or 'refused 
to answer' if applicable. If additional space is needed, document within the Interview/Investigation Comments (item 23).
Places had Sex: Document the codes (from above list) for the types of places where the patient had sex with partners 
within the last 12 months (document as many as apply); document the names (or descriptions) of the places the patient 
had sex with partners. Document 'did not ask' or 'refused to answer' if applicable. If additional space is needed, 
document within the Interview/Investigation Comments.
Interview, Internet, and Investigation Comments
Interview/Investigation Comments: This section is provided to record, in a narrative fashion, any additional information 
not included in the interview record, any relevant information discovered in the course of the investigation (such as 
attitude of the patient, if he or she was high/intoxicated, etc.), or to note any inconsistencies during the interview or DIS 
analysis of interview information. Also use this space to document any related internet use information, including 
alternate email addresses, instant messenger usernames, chat sites, etc. Also, note whether there were STD Clinic or 
provider accessability or availability issues that affected service to the patient.
Incidental Antibiotic Treatment in Last 12 Months
Place an “X ” in the appropriate box, Y - Yes, N - No, U - Unknown. If incidental antibiotic treatment occurred (that being 
an antibiotic that the patient did not receive to specifically treat this condition), document the date (MM/YYYY) the 
treatment began and the drug, dosage and duration used, and for what condition the treatment was prescribed, if known. 
If the date the treatment began is unknown, document “99/9999”.
